U.S. patent application number 12/688363 was filed with the patent office on 2010-07-08 for diagnostic methods using tenascin-w compositions.
Invention is credited to RUTH CHIQUET-EHRISMANN, Arnaud Scherberich.
Application Number | 20100173314 12/688363 |
Document ID | / |
Family ID | 9933815 |
Filed Date | 2010-07-08 |
United States Patent
Application |
20100173314 |
Kind Code |
A1 |
CHIQUET-EHRISMANN; RUTH ; et
al. |
July 8, 2010 |
DIAGNOSTIC METHODS USING TENASCIN-W COMPOSITIONS
Abstract
Tenascin-W. an extracellular matrix molecule that is
specifically expressed in metastatic tumours is provided. A system
comprising a sample expressing tenascin-W is used as an in vitro
method for screening possible anti-tumour agents or for agents that
promote osteogenesis.
Inventors: |
CHIQUET-EHRISMANN; RUTH;
(Reinach, CH) ; Scherberich; Arnaud; (Riedisheim,
FR) |
Correspondence
Address: |
HOXIE & ASSOCIATES LLC
75 MAIN STREET , SUITE 301
MILLBURN
NJ
07041
US
|
Family ID: |
9933815 |
Appl. No.: |
12/688363 |
Filed: |
January 15, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10509009 |
May 3, 2005 |
7683159 |
|
|
PCT/EP03/03150 |
Mar 26, 2003 |
|
|
|
12688363 |
|
|
|
|
Current U.S.
Class: |
435/6.14 ;
435/7.1; 436/501 |
Current CPC
Class: |
A61P 9/10 20180101; A61P
7/02 20180101; C07K 16/30 20130101; A61P 19/08 20180101; A61P 35/00
20180101; A61P 19/10 20180101; A61P 35/04 20180101; A61K 38/1709
20130101; C07K 14/78 20130101; A61P 17/02 20180101 |
Class at
Publication: |
435/6 ; 436/501;
435/7.1 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; G01N 33/566 20060101 G01N033/566; G01N 33/53 20060101
G01N033/53 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 27, 2002 |
GB |
0207224.7 |
Claims
1-52. (canceled)
53. A method of diagnosing or prognosing cancer comprising:
analysing a sample obtained from an individual for the presence of
tenascin-W protein or tenascin-W transcript; and determining the
presence of the tenascin-W protein or the tenascin-W transcript in
the sample by a detection method, wherein the detection of the
presence of the tenascin-W protein or the tenascin-W transcript in
the sample using the detection method indicates an unfavorable
prognosis or diagnosis.
54. The method of claim 53, wherein in the step of determining, the
presence of the tenascin-W protein or the tenascin-W transcript is
indicated by an elevated level of the tenascin-W protein or the
tenascin-W transcript in the sample, and the detection of the
elevated level of the tenascin-W protein or the tenascin-W
transcript in the sample relative to healthy tissue indicates the
unfavorable prognosis or diagnosis.
55. The method of claim 53, wherein the sample used in the step of
analyzing is blood serum or plasma from the individual.
56. The method of claim 55, wherein the tenascin-W protein is
detected in the detection method using an antibody specific for the
tenascin-W protein.
57. The method of claim 55, wherein the tenascin-W transcript is
detected in the detection method using a polymerase chain
reaction.
58. The method of claim 53, further comprising: analyzing the
sample for the presence of alpha 8 integrin expression; and
determining the presence of the alpha 8 integrin expression in the
sample by a second detection method, wherein the detection of the
presence of the alpha 8 integrin indicates an unfavourable
prognosis or diagnosis.
59. The method of claim 58, wherein the alpha 8 integrin is
detected in the second detection method using an antibody specific
for the alpha 8 integrin.
60. The method of claim 53, wherein the method further comprises:
propagating cells in the sample in cell culture.
61. The method of claim 53, wherein the step of analysing includes
a prior step of pre-treating the sample.
62. The method of claim 61, wherein the step of pre-treating
includes forming a cell extract.
63. The method of claim 53, wherein the step of analysing includes
detecting a control protein in the sample, and optionally
normalizing a value obtained for the tenascin-W protein or the
tenascin-W transcript with the control protein.
Description
[0001] The present invention relates to polypeptides specifically
expressed in tumours, to active agents having anti-tumour and/or
anti-tumourigenic activity and to agents effective in improving
conditions dependent on stem cell differentiation, in particular
osteoblast formation, such as in osteogenesis, to pharmaceutical
compositions of these agents and to the pharmaceutical uses of such
agents and compositions. The invention also relates to in vitro
methods of screening agents for anti-tumour and/or
anti-tumourigenic activity as well as for agents effective in
promoting stem cell differentiation.
[0002] The adherence of cells to each other and to the
extracellular matrix (ECM) as well as the cellular signals
transduced as a consequence of such binding are of fundamental
importance to the development and maintenance of body form and
function. The ECM has an important regulatory function in tissue
homeostasis and, together with oncogenes and tumour suppressor
genes is critically involved in tumourigenesis (reviewed in
Boudreau, N. & Bissell, M. J. (1998) Curr Opin Cell Biol 10:
640-646 and Kuoslahli, E. (1999) Adv Cancer Res 76:1-20).
[0003] In the more affluent countries of the world cancer is the
cause of death of roughly one person in live with the five most
common cancers being those of the lung, stomach, breast,
colon/rectum and the uterine cervix. Tumors of this type often
metastasize through lymphatic and vascular channels. Cancer is not
fatal in every case and only about half the number of people who
develop cancer die of it. The problem facing cancer patients and
their physicians is that seeking to cure cancer is like trying to
get rid of weeds.
[0004] One way to treat cancer effectively is to get an early
diagnosis. Most cancers are not extensively vascularized (and
therefore not invasive) during the early stages of development. The
transition to a highly vascularized, invasive and ultimately
metastatic cancer which spreads throughout the body commonly takes
ten years or longer. If the cancer is detected prior to invasion,
surgical removal of the cancerous tissue is an effective cure.
However, cancer is often detected only upon manifestation of
clinical symptoms. Generally, such symptoms arc present only when
the disease is well established, often after metastasis has
occurred, and the prognosis for the patient is poor, even after
surgical resection of the cancerous tissue. Early detection of
cancer therefore is important in that detection may significantly
reduce morbidity. A reliable, non-invasive, and accurate technique
or diagnosing cancer at an early stage would help save many
lives.
[0005] Cancer cells can be removed surgically or destroyed with
toxic compounds or with radiation but it is very hard to eliminate
all of the cancerous cells. A general goal is therefore to find
better ways or selectively killing cancer cells whilst leaving
normal cells of the body unaffected. Part of that effort involves
identifying new anti-cancer agents.
[0006] Apart from tumorgenesis, the ECM has an important regulatory
function in tissue homeostasis and in the development and
maintenance of body form and function, e.g. in the development or
remodeling of skeleton or in bone morphogenesis. Bone marrow has
stem cells with osteogenic potential and is made up of determined
osteogenic precursor cells that are committed to osteogenesis and
of inducible osteogenic precursor cells. Determined osteogenic
precursor cells can differentiate into bone without an exogenous
signal. Inducible osteogenic precursor cells require a molecular
signal for initiating the differentiation program, e.g. induction
by binding to extracellular matrix.
[0007] A number of molecules mediating cell adhesion have been
identified and characterized at the molecular level both in
vertebrates and invertebrates. Tenains are a family of large
multimeric extracellular matrix proteins, each having homologous
subunits built from variable numbers of repeated domains. These
include heptad repeats, epidermal growth factor (EGF)-like repeats,
fibronectin type III domains and a C-terminal globular domain which
is also found in fibrinogens. Tenascin-C was the first member of
the family to be discovered, in one instance as a muyotendious
antigen (Chiquet, M. & Fambrough, D M. (1984) J Cell Biol
98(6):1997-1946) and in another, as a protein enriched in the
stroman of gliomas (Bourdon, M A. et al (1983) Cancer Res
43(6):2796-2805, reflecting the major sites of tenascin-C
expression, namely in tendons and ligaments and the extra-cellular
matrix of tumor stroma. A further instance of the discovery of
tenascin-C (also termed hexabrachion) reflects its interaction with
fibronectin (Erickson, H P. et al. (1984) Nature 311(5983):267-9).
Enforced interaction of tumour cells with fibronectin can block
proliferation in cell culture and can decrease tumour growth in
nude mice (Arkamatsu H. et al (1996) Cancer Res 56: 4541-4546 and
Giancotti, F. G & Ruoslahti, E. (1990) Cell 60: 849-859).
Tenascin-C was shown to disrupt the interaction of cells with
fibronectin and in this manner may enhance tumour cell
proliferation. Chiquet-Ehrismann, R. et a. (1988) Cell 53: 383-390
were the first to show that tenascin-C binds to fibronection,
blocks cell attachment to fibronectin and increases proliferation
of rat breast adenocarcinoma cells (Chiquet-Ehrismann, R. et al
(1986) Cell 47: 131-139).
[0008] Tenascin-C is present in a large number of developing
tissues including the nervous system. Although abundant in mature
ligaments and tendons, it is absent from skeletal and heart muscle,
unless the muscle has been injured. Tenascin-C expression is
elevated in essentially all carcinomas as well as in many other
types of tumors (for review see Chiquet-Ehrismann, R. (1993) Semin
Cancer Biol 4(5):301-10). Furthmore, tenascin-C is upregulated in
would healing (Latijnhouwers, M A. et al (1996) J Patol
178(1):30-5), during skeletogenesis (Koyama, E. et al (1996) J
Orthop Res. 14(3):403412 and Hall, B K. & Miyake, T. (1995) Int
J Dev Biol. 39(6):881-893) as well as in many diseases involving
infections and inflammation (Schenk, S. et al. (1995) Int J Cancer
61(4):443-9).
[0009] Each tenascin family member exhibits a specific gene
expression pattern during embryogenesis and in the adult (for
review see Chiquet-Ehrismann, R. (1995) Experientia
51(9-10):853-62) suggesting specific roles for each member.
Tenascin-R is an extracellular matrix component of the nervous
system found mainly in brain tissue (Pasheva, P. et al. (2001) Prog
Brain Res. 132:103-14. Review), whereas tenascin-X is prominently
expressed in muscle and skin connective tissue. In one patient,
tenascin-X deficiency has been reported to result in an Ehler'3 s
Danlos phenotype (Burch, G H. et al. (1997) Nat Genet
17(1):104-8).
[0010] To date there is only one report on tenascin-W available in
the literature. (Weber, P. et al. (1998) J Neurobiol 35(1):1-16).
In this study, a cDNA encoding tenascin-W was isolated from a 20-28
h postfertilization zebralish cDNA library on the basis of the
conserved epidermal growth factor-like domains found in all
tenascin molecules. The expression pattern of tenascin-W
transcripts was studied in the developing zebralish by in situ
hybridisation. It was found to be present in neural crest and
selerotome cells and the developing skeleton. Genebank sequence
AJ001423 provides a zebralish tenascin-W, and AL049689 provides a
"novel human mRNA from chromosome 1, similar to Tenascin-R", whose
function is not known.
[0011] The present invention provides a composition comprising an
isolated nucleic acid molecule having a nucleotide sequence
selected from the group consisting of: [0012] (a) a nucleotide
sequence as set forth in SEQ ID NO: 1; [0013] (b) a nucleotide
sequence encoding the amino acid sequence shown in SEQ ID NO: 2;
[0014] (c) a nucleotide sequence with at least 85% identity to the
sequence of (a) or (b); [0015] (d) a subsequence of more than 50
consecutive nucleotides of a sequence of (a), (b) or (c); and
[0016] (e) a nucleotide sequence complementary to any of the
nucleotide sequences or subsequence in (a), (b), (c) or (d).
[0017] In one aspect of the invention, the isolated nucleic acid
molecule having a nucleotide sequence preferably (a); preferably
encoding a variant of the amino acid sequence shown in SEQ ID NO:
2, such as a variant comprising an amino acid deletion, addition
(e.g. fusion proteins) or substitution of the amino acid sequence
shown in SEQ ID NO:2. Preferably, the variant comprises a
conservative substitution of at least one amino acid in said amino
acid sequence in SEQ ID: NO: 2, more preferably the variant has
stem cell differentiation inducing activity, in particular an
activity that induces osteoblast development from stem cells. Most
preferred is when the isolated nucleic acid molecule encodes a
protein with the amino acid sequence shown in SEQ ID NO: 2.
[0018] The nucleic acid molecule can be an antisense molecule, in
which case it might be desirable to have nucleotide residues that
are resistant to nuclease degradation substituting some or all of
the ribo- or deoxyribonucleolidcs.
[0019] Also provided are nucleic acid vectors comprising the
nucleic acid molecules of the invention, as well as host cells
comprising the vectors or nucleic acids, and transgenic, knockout
or genetically modified animals (other than humans, in particular
mice), comprising manipulated nucleic acids of the invention or
absent the endogenous sequence.
[0020] The invention also provides a composition comprising an
isolated polypeptide having an amino acid sequence selected from
the group consisting of: [0021] (a) an amino acid sequence as set
forth in SEQ ID No. 2; and [0022] (b) an amino acid sequence with
at least 85% identity to the sequence of (a); and [0023] (c) a
subsequence of at least 30 consecutive amino acids of the sequence
of (a) or (b), with the proviso that said subsequence does not fall
within amino acid nos. 1102 and 1152 of SEQ ID NO:2.
[0024] Preferably, the amino acid sequence in (b) comprises a
conservative substitution of at least one amino acid of the amino
acid sequence of SEQ ID: NO: 2. More preferably, the polypeptide or
fragment has stem cell differentiation inducing activity, as
described above. Useful fragments may exhibit an epitope recognized
by polyclonal antibodies raised against the polypeptide having the
amino acid sequence shown in SEQ ID NO: 2, for example. A
particularly preferred polypeptide is that encoded by the amino
acid sequence shown in SEQ ID NO: 2.
[0025] Also provided are antibodies that are specifically reactive
against the polypeptides of the invention.
[0026] In another aspect of the invention, a composition comprising
an isolated nucleic acid molecule having a nucleotide sequence
selected from the group consisting of: [0027] (a) a nucleotide
sequence as set forth in SEQ ID No. 1 or SEQ ID No. 3; [0028] (b) a
nucleotide sequence encoding the amino acid sequence shown in SEQ
ID NO: 2 or SEQ ID NO: 4; [0029] (c) a nucleotide sequence with at
least 35% identity to any one of the sequences of (a) or (b),
preferably (a); [0030] (d) a subsequence of a least 15 consecutive
nucleotides of the sequence of (a), (b) or (c); and, [0031] (e) a
nucleotide sequence complementary to (a), (b), (c), or (d), and a
pharmaceutically acceptable excipient, diluent or carrier.
[0032] In one embodiment, the nucleic acid molecule preferably
encodes a protein having stem cell differentiation inducing
activity. In another embodiment, the nucleic acid molecule has a
subsequence that is antisense to SEQ ID NO:1 or SEQ ID NO:3,
wherein the nucleic acid molecule may comprise nucleotide residues
that are resistant to nuclease degradation. In another embodiment,
the isolated nucleic acid molecule encodes the amino acid sequence
shown in SEQ ID NO: 2 or SEQ ID NO:4. In yet another embodiment,
the nucleic acid molecule has a subsequence selected from the group
consisting of nucleotides 2380-3171 of SEQ ID No:1, nucleotides
2371-3162, of SEQ ID No:3, a complement of nucleotides 2380-3171 of
SEQ ID No:1, and a complement of nucleotides 2371-3162 of SEQ ID
No:3, or an RNA equivalent thereof.
[0033] Thus, also provided are nucleic acid compositions as
described above for use as a pharmaceutical, as well as the use of
such compositions for the manufacture of a medicament for the
prophylaxis or treatment of cancer or bone pathologies.
[0034] Also provided are compositions comprising tenascin-W,
preferably recombinant tenascin-W, and a pharmaceutically
acceptable excipient, diluent or carrier. In preferred embodiments,
the tenascin-W is a polypeptide having an amino acid sequence
selected from the group consisting of: [0035] (a) an amino acid
sequence asset forth in SEQ ID No. 2 or 4; [0036] (b) an amino acid
sequence with at least 35% identity to the sequence of (a); and
[0037] (c) a subsequence of at least 30 consecutive amino acids of
the sequence of (a) or (b).
[0038] Preferably, the polypeptide has stem cell differentiation
inducing activity as described above. More preferably, the
polypeptide is encoded by the amino and sequence shown in SEQ ID
NO: 4.
[0039] Thus, also provided is the use of tenascin-W for treatment
or prophylactic treatment of any disease or condition requiring
increased tenascin-W levels, e.g. thrombosis, wound healing or
atherosclerosis, as well as a condition ameliorated by the
promotion of osteogenesis, e.g. bone healing, osteoporosis, as well
as the use of tenascin-W as a stem cell marker.
[0040] Also provided arc antibodies that specifically recognizes
tenascin W for use as a pharmaceutical, as well as for the
manufacture of a medicament, for the prophylaxis or treatment of
cancer (e.g., glioblastoma, prostate, lung, colorectal, osteo- or
breast carcinoma), including metastatic cancer, or for the
prophylaxis or treatment of any disease or condition involving
tenascin-W, e.g. excessive bone growth.
[0041] The present invention also provides methods tor identifying
agents for the prevention or the prophylactic treatment of
tumourigenesis or the treatment or prophylactic treatment of
tumours or cancer, or the treatment or prophylactic treatment of
any disease or condition involving tenascin-W, e.g. a condition
ameliorated by the promotion or inhibition of osteogenesis,
comprising contacting a test compound with a tenascin-W expressing
cell sample and then measuring a change in one or more of: [0042]
(a) cell proliferation, e.g. cell progression entering S-phase of
the cell cycle; [0043] (b) DNA synthesis; [0044] (c) cell adhesion;
[0045] (d) cell spreading; [0046] (e) focal adhesion and actin
stress fibre formation on fibronectin; and [0047] (f) cell binding
to extracellular matrix (ECM)
[0048] relative to when said test compound is absent.
[0049] Optionally, the method further comprises measuring a change
in tenascin-W expression relative to when the test compound is
absent. The tenascin-W may have any one-or more of the features
described above. A particularly preferred assays is carried out in
the form of an enzyme linked immunosorbent assay (ELISA).
[0050] Also provided is a method for identifying modulators of
tenascin W function, comprising: [0051] (a) contacting a test
compound with tenascin W and/or alpha8 beta1 integrin, and [0052]
(b) measuring the binding of the test compound to tenascin-W and/or
alpha8 beta1 integrin, or [0053] (c) measuring a disruption of
binding of tenascin-W to alpha8 beta1 integrin, [0054] relative to
when the test compound is absent.
[0055] Optionally the method further comprises measuring the
binding of a control compound to tenascin-W. In one embodiment, the
tenascin-W is attached to a solid surface, for example using an
antibody reactive against tenascin-W. The binding can be
conveniently detected using an antibody labelled with a fluorescent
label, a fluorescence quencher, a radioactive label, a scintilant
or an enzyme. Alternatively, the binding is detected by measuring
the adhesion of alpha8 beta1 to the immobilized tenascin-W (as
described in example 8) or vice versa. A decrease in binding of
tenascin-W to alpha8 beta1 integrin is indicative of an inhibitor
of the tenascin-W to alpha8 beta1 integrin is indicative of an
inhibitor of the tenascin-W to alpha8 beta1 integrin interaction
(and therefore an inhibitor of tenascin W function). An increase in
binding of tenascin-W to alpha8 beta1 integrin in the presence of a
test compound is indicative of a potential agent that activates
alpha8 beta1 integrin, thereby acting as an agonist of tenascin-W
function.
[0056] Thus also provided, are agents for the prevention or the
prophylactic treatment of tumourigenesis or the diagnosis or the
treatment or prophylatic treatment of tumours, or the treatment or
prophylactic treatment of any disease or condition involving
tenascin-W, e.g. a condition amelorated by the promotion of
osteogensis, identified by a screening method of the invention.
[0057] Also provided are methods of diagnosing or prognosing cancer
comprising: [0058] (a) analysing a sample obtained from an
individual for the presence of tenascin-W; and [0059] (b)
correlating the presence of tenascin-W with an unfavourable
prognosis or diagnosis.
[0060] Optionally, the method may further comprise correlating in
an increase in (elevated level of) tenascin-W in the sample
relative to healthy tissue with an unfavourable prognosis or
diagnosis. Tenascin-W can be conveniently detected using an
antibody specific for tenascin-W or alternatively tenascin-w can be
detected at the transcript level using techniques well known in the
art, such as a polymerase chain reaction (e.g., RT-PCR). The method
may also include the additional use of controls.
[0061] The sample can be blood serum from an individual, for
example. The method may also further comprise propagating cells in
a sample in cell culture. In one embodiment, the method further
comprises analysing the sample for the presence of alpha 8
integrin, the presence of alpha 8 integrin correlating with an
unfavourable prognosis or diagnosis.
[0062] The present inventors have investigated extractular matrix
molecules, their expression during development, cell adhesion and
proliferation of tumour cells and have characterized a novel member
of the mammalian tenascin family. Prior to the present invention,
no tenascin-W had been identified from a mammalian source and its
function was not previously known. The present inventors have
identified and characterized the complete cDNA sequence encoding
the mouse and human tenascin-W. Anti-sera were prepared against a
fragment of tenascin-W, which detect tenascin W in tumour stroma,
in the periosteum and in liver tissue, and cross react with
tenascin W from several mammalian species. In particular, the
inventors have discovered that tenascin-W is specifically expressed
in metastatic tumour cells as well as in the periosteum, the stem
cell compartment for osteogenesis.
[0063] Thus in one aspect, the present invention provides a
composition comprising an Isolated nucleic acid molecule having a
nucleotide sequence selected from the group consisting of: [0064]
(a) a nucleotide sequence as set forth in SEQ ID NO: 1; [0065] (b)
a nucleotide sequence encoding the amino acid sequence shown in SEQ
ID NO: 2; [0066] (c) a nucleotide sequence with al least 85%
identity to the sequence of (a) or (b); [0067] (d) a subsequence of
more than 50, 75, 100, 200 or more consecutive nucleotides of a
sequence of (a), (b) or (c); and [0068] (e) a nucleotide sequence
complementary to any of the nucleotide sequences or subsequence in
(a), (b), (c) or (d).
[0069] The compositions include various types of nucleic acid,
including genomic DNA, cDNA and mRNA, for example. In one aspect of
the invention, the isolated nucleic acid molecule having a
nucleotide sequence preferably exhibits at least 85%, identity,
more preferably 90% identity, most preferably 95, 98 or 100%
identity to the sequence of (a) (SEQ ID NO:1). Also encompassed are
nucleic acids that encode polypeptides having the amino acid
sequence shown in SEQ ID NO: 2, or variants thereof such as a
variant comprising an amino acid deletion, addition (e.g. fusion
proteins) or substitution relative to the amino acid sequence shown
in SEQ ID NO:2. The various nucleic acids that can encode these
polypeptides therefore may differ because of the degeneracy of the
genetic code, in that most amino acids are encoded by more than one
triplet codon. The identity of such codons is well known in this
art, and this information can be used for the cons ruction of the
nucleic acids within the scope of the invention. Variants differ
from wild-type protein in having one or more amino acid
substitutions that either enhance, add, or diminish a biological
activity of the wild-type protein. Once the amino acid change is
selected, a nucleic acid encoding that variant is constructed
according to methods well known in the art.
[0070] Preferably, the variant comprises a conservative
substitution of at least one amino acid in said amino acid sequence
in SEQ ID: NO: 2. The variant will typically exhibit a biological
function of the polypeptide as set forth in SEQ ID NO:2, that is,
stem cell differentiation inducing activity, in particular an
activity that induces osteoblast development from stem cells, or
binding to an antibody that specifically recognizes Tenascin-W. To
maintain biological activity, only conservative substitutions are
therefore preferred as is well known in the art. Most preferred is
when the isolated nucleic acid molecule encodes a protein with the
amino acid sequence shown in SEQ ID NO: 2.
[0071] The nucleic acid molecule can be an antisense molecule, in
which case it might be desirable to have nucleotide residues that
are resistant to nuclease degradation substituting some or all of
the ribo- or deoxyribonucleotides. Such nucleotide residues
resistant to nucleases are well known in the art and can be easily
synthesized by chemical means.
[0072] Also provided are nucleic acid vectors comprising the
nucleic acid molecules of the invention, as well as host cells
comprising the vectors of nucleic acids, and transgenic, knockout
or genetically modified animals (other than humans, in particular
mice), comprising manipulated nucleic acids of the invention or
absent the endogenous sequence.
[0073] The invention also provides a composition comprising an
isolated polypeptide having an amino acid sequence selected from
the group consisting of: [0074] (a) an amino acid sequence as set
forth in SEQ ID NO: 2; [0075] (b) an amino acid sequence with at
least 85% identity, preferably 90, 95, 98 or 100% identity to the
sequence of (a); and [0076] (c) a subsequence of at least 30, 40,
50, 75, 100 or more consecutive amino acids of the sequence of (a)
or (b), with the proviso that said subsequence does not fall within
amino acid nos. 1102 and 1152 of SEQ ID NO:2.
[0077] Preferably, the amino acid sequence in (b) comprises a
conservative substitution of at least one amino acid of the amino
acid sequence of SEQ ID: NO: 2. More preferably, the polypeptide or
fragment has stem cell differentiation inducing activity, as
described above. Useful fragments may exhibit an epitope recognized
by polyclonal antibodies raised against the polypeptide having the
amino acid sequence shown in SEQ ID NO: 2, for example. A
particularly preferred polypeptide is that encoded by the amino
acid sequence shown in SEQ ID NO: 2, derived from mouse tissue.
[0078] Therefore, also included within the invention are variants
and derivatives of the polypeptide described by SEQ ID NO:2 or
fragment thereof, whether produced by recombinant means or
synthetic means or isolated from naturally occurring sources. For
example, peptides having modified amino acids/peptide linkages, and
peptides containing non-naturally occurring amino acids and/or
cyclic peptides, which may have improved properties such as
stability or activity are included. In addition the peptides of the
inventing may be in the form or a fusion with another protein, for
example, tags for the targeted delivery or detection, or
purification of the polypeptide (including fragments thereof.
[0079] A "variant" in terms of amino acid sequence defines an amino
acid sequence that differs by one or more amino acids from another,
usually related amino acid sequence. The variant may have
"conservative" changes, wherein a substituted amino acid has
similar structural or chemical properties (e.g. replacement of
leucine with isoleucine). Less likely, a variant may have
"on-conservative" changes, e.g. replacement of a glycine with a
tryptophan. Similar minor variations may also include amino acid
deletions or insertions (i.e. additions), or both. Guidance in
determining which and how many amino acid residues may be
substituted, inserted or deleted without abolishing activity (e.g.,
anti-cancer activity, osteoblast promoting activity, antigenic
activity) may be found using computer programs well known in the
art. Variants of the polypeptides of the invention include all
forms of mutant variants, for example wherein at least one amino
acid is deleted or substituted. Any changes involving substitution
of amino acids are preferably neutral or conservative
substitutions. Other variants include proteins or polypeptides
comprising al least one additional amino acid in the sequence,
and/or further comprising an additional amino acid sequence or
domain, such as fusion proteins, as is well known in the art.
[0080] Further variants of the polypeptides of the invention
include those wherein at least one of the amino acids in the
sequence is a natural or unnatural analogue. Also, one or more
amino acids in the sequence may be chemically modified, e.g. to
increase physical stability or to lower susceptibility to enzymic,
particularly protease or kinase, activity.
[0081] Also provided are antibodies that are specifically reactive
against the polypeptides of the invention. Methods for producing
antibodies are well known in the art. An antibody specific for the
polypeptide of the invention can be easily obtained by immunizing
an animal with an immunogenic amount of the polypeptide. Therefore,
an antibody recognizing the polypeptide of the invention embraces
polyclonal antibodies and antiserum which are obtained by
immunizing an animal, and which can be confirmed to specifically
recognize the polypeptide of the invention by Western blotting,
ELISA, immunostaining or other routine procedure known in the
art.
[0082] It is well known that if a polyclonal antibody can be
obtained by sensitization, a monoclonal antibody secreted by a
hybridoma may be obtained from the lymphocytes of the sensitized
animal (Chapter 6, Antibodies A Laboratory Manual, Cold Spring
Harbor Laboratory Press, 1988). Therefore, monoclonal antibodies
recognizing the polypeptide of the invention are also provided.
Methods of producing polyclonal and monoclonal antibodies are known
to those of skill in the art and described in the scientific and
patent literature, see, e.g., Coligan, Current Protocols in
Immunology, Wiley/Green, NY (1991); Stites (eds.) Basic and
Clinical Immunology (7th ed.) Lange Medical Publications, Los
Altos, Calif., and references cited therein (Stites); Goding,
Monoclonal Antibodies: Principles and Practice (2nd ed.) Academic
Press, New York, N.Y. (1986); and Kohler (1975) Nature 256: 495.
Such techniques include selection of antibodies from libraries of
recombinant antibodies displayed in phage or similar on cells. See,
Huse (1989) Science 246: 1275 and Ward (1989) Nature 341: 544.
Recombinant antibodies can be expressed by transient or stable
expression vectors in mammalian cells, as in Norderhaug (1997) J.
Immunol Methods 204: 77-87.
[0083] In this invention, an antibody a so embraces an active
fragment thereof. An active fragment means a fragment of an
antibody having activity of antigen-antibody reaction. Specifically
named, these are active fragments, such as F(ab')2, Fab', Fab, and
Fv. For example, F(ab')2 results it the antibody of this invention
is digested with pepsin, and Fab results if digested with papain.
Fab' results if F(ab')2 is reduced with a reagent such as
2-mercaptoetbanol and alkylated with monoiodoacetic acid. Fv is a
monoactive fragment where the variable region of heavy chain and
the variable region of light chain are connected with a linker. A
chimeric antibody is obtained by conserving these active fragments
and substituting the fragments of another animal for the fragments
other than these active fragments. In particular, humanized
antibodies are envisioned.
[0084] The nucleic acid and polypeptide sequences investigated
herein have been found to be differentially expressed in samples
obtained from metastatic cancer cell lines and are predicative of
tenascin-W expression in metastatic cancer tissue, as well as in
other types of cancer and diseases.
[0085] Accordingly, certain aspects of the present invention relate
to nucleic acids differentially expressed in tumour tissue,
especially metastatic cancer cell lines, polypeptides encoded by
such nucleic acids, and antibodies immunoreactive with these
polypeptides, and preparations of such compositions. Moreover, the
present invention provides diagnostic and therapeutic assays and
reagents for detecting and treating disorders involving, for
example, aberrant expression of the subject nucleic acids.
[0086] Thus, in a further aspect of the invention, a composition is
provided comprising an isolated nucleic acid molecule encoding
tenascin W or a fragment thereof and a pharmaceutically acceptable
excipient, diluent or carrier. The pharmaceutical use of nucleic
acids encoding tenascin W had not previously been suggested and
therefore in this embodiment, the nucleic acids of the
pharmaceutical compositions are not limited to the nucleic acids of
the invention. In particular, the composition may comprise an
isolated nucleic acid having a nucleotide sequence selected from
the group consisting of: [0087] (a) a nucleotide sequence as set
forth in SEQ ID No. 1 or SEQ ID No. 3 (encoding human tenascin W);
[0088] (b) a nucleotide sequence including the amino acid sequence
shown in SEQ ID NO: 2 or SEQ ID NO: 4; [0089] (c) a nucleotide
sequence with at least 35% identity, preferably at least 40, 50,
60, 70, 80, 90, 95 or 100% identity to any one of the sequences of
(a) or (b), preferably (a); [0090] (d) a subsequence of at least
10, 15, 20, 25, 30, 40, 50, 75, 100 or more consecutive nucleotides
of the sequence of (a), (b) or (c); and [0091] (e) a nucleotide
sequence complementary to (a), (b), (c), or (d), and a
pharmaceutically acceptable excipient, diluent or carrier.
[0092] In one embodiment, the nucleic acid molecule encodes
tenascin-W having the amino acid sequence as set forth in SEQ ID
No. 2 or SEQ ID NO. 4 or an amino acid with at least 30%,
preferably at least 50%, 70%, 80%, 90%, 95%, or 100%, identity to a
sequence corresponding to SEQ ID NO:2 or 4. The nucleic acid
molecules are at least 10, preferably at least 15, 20, 30, 50, 75,
100 or more consecutive nucleotides of SEQ ID No. 1 or SEQ ID No.2
or a sequence complementary thereto.
[0093] In one embodiment, the invention provides a composition
comprising a nucleotide sequence fragment selected from the group
consisting of nucleotides 2380-3171 of SEQ ID No:1 or nucleotides
2371-3162 of SEQ ID No:3, a complement of nucleotides 2380-3171 of
SEQ ID No: 1 or of nucleotides 2371-3162 of SEQ ID No:3, and RNA
equivalents thereof, which encode an epitope for the binding with
an antibody paratope.
[0094] In another embodiment, the nucleic acid molecule preferably
encodes a protein having stem cell differentiation inducing
activity. Although it is well within the skill of the art to
identify polypeptides with the appropriate activity using routine
methodology, the isolated nucleic acid molecule preferably encodes
the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO:4, most
preferably that of SEQ ID NO:4.
[0095] In yet another embodiment, the nucleic acid molecule has a
subsequence that is antisense to SEQ ID NO: 1 or SEQ ID NO:3,
wherein the nucleic acid molecule may comprise nucleotide residues
that arc resistant to nuclease degradation.
[0096] The nucleic acid may be antisense to all or a part of a
nucleic acid which hybridizes under stringent conditions to SEQ ID
No: 1 or SEQ ID No:3, or antisense to a sequence having at least
70% identity with SEQ ID NO:1 or SEQ ID NO:3, that is able to
hybridize under low stringency conditions to SEQ ID NO:1 or SEQ ID
NO:3, and which encodes tenascin-W. Low stringency conditions
employs around 0.01.times.SSC buffer compared to high stringency
which employs about a 10 fold greater concentration. Alternatively,
the antisense RNA may be antisense to regulatory sequences of the
tenascin-W gene, in particular to 5' upstream sequences (promoter
region) of the gene. Similarly, small RNAI oligonucleoties can be
designed to inhibit expression of Tenascin-W in a specific
manner.
[0097] The nucleic acids can be RNA or DNA, sense or antisense, and
in some embodiments, double stranded (including siRNA) or single
stranded. In certain embodiments at least some of the nucleotide
residues of the nucleic acids (sense or antisense) may be made
resistant to nuclease degradation and these can be selected from
residues such as phophorothioates and/or methylphosphonates.
[0098] The antisense nucleic acids as hereinbefore described can
advantageously be used as pharmaceuticals, preferred pharmaceutical
applications being for the manufacture of a medicament for the
prophylaxis or treatment of cancer.
[0099] Thus, the invention also provides a method of preventing or
treating a condition dependent on Tenascin W, comprising
administering to an individual an effective amount of a nucleic
acid, as hereinbefore described. Thus, the invention encompasses
the use of such nucleic acid molecules as a pharmaceutical, as well
as for the manufacturer of a medicament, in particular for the
prophylaxis or treatment of cancer or bone pathologies.
[0100] In yet another aspect, the present invention provides
expression vectors capable of replicating in a host cell,
comprising one or more vector sequences and a nucleic acid sequence
encoding tenascin-W. The construct for use as a pharmaceutical is
also provided, as well as its use for the manufacture of a
medicament for the prophylaxis or treatment of cancer or the
prophylaxis or treatment of bone pathologies.
[0101] Other embodiments of the invention include nucleic acid
constructs capable of replicating in a host cell, comprising (a) at
least one nucleic acid sequence portion encoding a tenascin-W
protein or polypeptide of the invention (b) antisense nucleic acids
as hereinbefore described (or their complement, for example, if
expression of the antisense RNA in a cell is foreseen), or (c)
nucleic acids as hereinbefore described and at least one nucleic
acid sequence encoding a protein other than tenascin-W (or its
homologues), e.g. vector sequence. Such constructs are not
naturally occurring sequences. The constructs lack essential
sequences of DNA which might permit them to function as vectors but
are not naturally occurring as "hybrid" nucleic acids. They may
include nucleic acid sequences that function as linkers or
restriction sites which include without limitation a
transcriptional regulatory sequence operably linked to a nucleotide
sequence of the invention so as to render said nucleic acid
construct capable of replicating in a host cell. Preferred
constructs are synthesised using methods of oligonucleotides
synthesis well known to those of skill in the art.
[0102] Also provided are vectors comprising a construct as
hereinbefore described. Preferred vectors are expression vectors,
preferably plasmids or viruses although cloning vectors are also
provided for, optionally in the form of plasmids.
[0103] The invention provides host cells containing vectors.
Preferred host cells are eukaryotic cells, more preferably insect
cells or mammalian cells.
[0104] Constructs, vectors and transformed host cells of the
invention are of use as pharmaceuticals, as well as for the
manufacture of a medicament for the prophylaxis or treatment of a
condition dependent on tenascin W, such as cancer or home
disorders.
[0105] Similarly, in a further aspect of the invention, a
composition is provided comprising tenascin W, preferably
recombinant tenascin-W, or a fragment thereof and a
pharmaceutically acceptable excipient, diluent or carrier. In
preferred embodiments, the tenascin-W is a polypeptide having an
amino acid sequence selected from the group consisting of: [0106]
(a) an amino acid sequence as set forth in SEQ ID No. 2 or 4;
[0107] (b) an amino acid sequence with at least 35% identity,
preferably at least 50%, 70%, 80%, 90%, 95%, or 99% identity to the
sequence of (a); and [0108] (c) a subsequence of at least 5, 10,
15, 20, 30, 50, 75, 100 or more consecutive amino acids of the
sequence of (a) or (b).
[0109] Preferably, the polypeptide has stem cell differentiation
inducing activity as described above. More preferably, the
polypeptide is encoded by the amino acid sequence shown in SEQ ID
NO:4.
[0110] Thus, also provided is the use of tenascin-W for the
treatment or prophylactic treatment of any disease or condition
requiring increased tenascin-W levels, e.g. thrombosis, wound
healing or atherosclerosis, as well as a condition ameliorated by
the promotion of osteogensis, e.g. bone healing, osteoporosis, as
well as the use of tenascin-W as a stem cell marker. In yet a
further aspect, the tenascin-W protein is used as a
pharmaceutical.
[0111] The present invention further provides the use of a
tenascin-W, e.g. for the manufacture of a medicament, for the
prevention or prophylactic treatment of tumourigenesis or the
treatment or prophylactic treatment of tumours or cancer. The
invention also includes the use of the tenascin-W or for the
manufacture of a medicament for the treatment or prophylactic
treatment of any one or more of bone disease, rheumatism, asthma,
allergic diseases, autoimmune diseases, prevention of transplant
rejection and any other diseases involving tenascin e.g.
thrombosis, cancer, wound healing and artherosclerosis.
[0112] The invention therefore provides pharmaceutical compositions
for humans or veterinary compositions for animal use that comprise
one or more of the aforementioned active fragments of tenascin-W.
The compositions may also include other active or non-active
agents. Non-active agents may include a pharmaceutically acceptable
excipient, diluent or carrier, but not limited to saline, buffered
saline, dextrose and water.
[0113] The compositions and medicaments of the invention may
therefore be used prophylaelically in order to prevent tumours from
forming, or they may be used in a curative or partly curative way
to treat or contain a pre-existing tumourous condition. As well as
tumours, cancerous or malignant conditions may be prevented or
treated with compositions or medicaments of the invention.
[0114] In a particular aspect, the present invention provides the
use of the nucleic acid or proteins or polypeptides as hereinabove
described, for radioimmunotherapy. Use of radiolabeled antibody is
a promising approach to target radiotherapy directly into the
tumor. Anti-tenascin-C antibodies are currently tested in phase I
and II clinical trials. Patients with malignant gliomas were
administrated locoregional radioimmunotherapy (LR-RIT) using
.sup.131I labeled anti-tenascin antibody injected directly in the
tumor (Riva et al., 1999a). The first results show that IR-RIT can
be safely performed, with good results especially in patients with
minimal disease. Similar approach was performed with .sup.90Y (a
pure beta emitter)-labeled antibodies Riva el al., 1999b), with
promising results. Potentially more efficient radioimmunotherapics
were shown to be possible using other isotopes, like in the case of
an .sup.211At-labeled anti-tenascin antibody (Zalutsky et al.,
2001), without excessive toxicity for the patient. It is as well a
useful tool for precise imaging of tumors, since the presence of
isotopes specifically targeted into the tumor allows sequential
scintigraphies of the tumor (Riva el al., 1999a), and makes
possible a direct estimation of the success of the therapy. Similar
methodologies can be applied using antibodies specific for
tenascin-w.
[0115] The tumours or tumor cells of the present invention are
preferably those which express tenascin-W in the stroma. In
particularly preferred embodiments the tumours are solid tumours,
e.g. mesenchymal tumours such as osteosarcoma, glioblastoma or
epithelial cancers such as breast, prostate, lung and colorectal
carcinoma.
[0116] The invention further provides the use of tenascin-W for the
treatment or prophylactic treatment of a condition ameliorated by
the promotion of osteogenesis, e.g osteoporosis, osteoarthritis,
treatment of cartilage and bone pathologies. A protein or
polypeptide as hereinabove described may be used to be incorporated
into implants including without limitation hip joints, knee joints,
or broken bones, to promote osteogensis.
[0117] The invention also provides a method of preventing or
prophylatic treatment of tumourigenesis or of treatment or
prophylactic treatment of tumours or cancer or of any one or more
of rheumatism, asthma, allergic diseases, autoimmune diseases,
prevention of transplant rejection or the treatment or prophylactic
treatment of any disease involving tenascin-W, e.g., thrombosis,
wound healing and atherosclerosis in an individual comprising
administering an effective amount of a tenascin-W or a fragment
thereof.
[0118] The invention also provides a method of treatment or
prophylactic treatment of a condition ameliorated by the promotion
of osteogenesis, e.g. osteoporosis, osteoarthritis, treatment of
cartilage and bone pathologies in an individual comprising
administering an effective amount of tenascin-W or a fragment
thereof.
[0119] The determination of an effective dose is well within the
capability of those skilled in the art. For any compound, the
therapeutically effective dose can be estimated initially either in
cell culture assays or in an appropriate animal model. The animal
model is also used to achieve a desirable concentration range and
route of administration. Such information can then be used to
determine useful doses and routes for administration in humans.
[0120] A therapeutically effective dose refers to that amount of
active agent which ameliorates the symptoms or condition.
Therapeutic efficacy and toxicity of such compounds can be
determined by standard pharmaceutical procedures in in cell
cultures or experimental animals (e.g., ED.sub.50, the dose
therapeutically effective in 50% of the population; and LD.sub.50,
the dose lethal to 50% of the population). The dose ratio between
therapeutic and toxic effects is the therapeutic index, and it can
be expressed as th ratio, LD.sub.50/ED.sub.50. Pharmaceutical
compositions which exhibit large therapeutic indices are preferred.
The data obtained from cell culture assays and animal studies is
used in formulating a range of dosage for human use. The dosage of
such compounds lies preferably within a range of circulating
concentrations that include the ED.sub.50 with little or not
toxicity. The dosage varies within this range depending upon the
dosage from employed, sensitivity of the patient, and the route of
administration.
[0121] The exact dosage may be chosen by the individual physician
in view of the patient to be treated. Dosage and administration can
be adjusted to provide sufficient levels of the active moiety or to
maintain the desired effect. Additional factors which may be taken
into account include the severity of the disease state (e.g. tumour
size and location); age, weight and gender of the patient; diet;
time and frequency of administration; drug combination(s); reaction
sensitivities; and tolerance/response to therapy. Long acting
pharmaceutical compositions can be administered on a daily basis,
every 3 to 4 days, every week, or once every two weeks, depending
on half-life and clearance rate of the particular formulation.
[0122] The present inventors have observed stem cells, especially
the periosteum, the stem cell compartment for osteogenesis,
expressing tenascin-W and therefore also encompassed by the
invention is a method of the invention, wherein tenascin-W is used
as a stem cell marker for cells including without limitation
osteogenic precursor cells in the bone marrow. Therefore, also
provided is a method of selecting stem cells or progenitor cells
having the ability to differentiate into osteoblasts from other
cells, not having this ability. Stem cells expressing tenascin-W
can be detected by an antibody. The antibody recognizing tenascin-W
can be detected using secondary antibodies specific for the
tenascin-W antibody, which are optionally labelled with a
radio-label, an enzyme, avidin or biotin, or fluorescent materials
(e.g. green fluorescent protein (GFP) or rhodamine), for example.
The cells are characterized by having tenascin-W expression above
basal levels and arc preferably selected from a mixed population of
cells using the fluorescence-activated cell sorter (FACS) (see for
example Abe et al., Dev Biol. 1996; 180(2):468-72). The selected
cells therefore carry a protein delectable by fluorescence. The
sorted cells are useful for the production of biological parts of
the body, e.g. bone tissue.
[0123] Also provided are antibodies that specifically recognizes
tenascin W for use as a pharmaceutical, as well as for the
manufacture of a medicament, for the prophylaxis or treatment of
cancer (e.g., glioblastoma, prostate, lung, colorectal, osleo- or
breast carcinoma), including metastatic cancer, or for the
prophylaxis or treatment of any disease or condition involving
tenascin-W, e.g. excessive bone growth. In another aspect of the
present invention, an antibody specifically reactive against
tenascin-W or a fragment thereof, and the use or an antibody for
the manufacture of a medicament for the prophylaxis or treatment of
cancer, and the antibody for use as pharmaceutical is provided.
[0124] Antibodies that specifically recognize tenascin-W or a
fragment thereof are also provided, in particular anti-bodies that
recognise the above mentioned epitope.
[0125] Methods for detecting tenascin-W embrace, for example, the
use of an antibody as referred to above, optionally with the use of
an enzyme reaction. The antibody recognizing tenascin-W can be
detected using secondary antibodies specific for the tenascin-W
antibody, which are optionally labelled with a radiolabel, an
enzyme, avidin or biotin, or fluorescent materials (FITC or
rhodamine), for example.
[0126] Also encompassed by the invention is the use of an antibody
that specifically recognizes tenascin-W for the manufacture of a
medicament, in particular a medicament for the prophylaxis or
treatment of cancer, the prophylaxis or treatment of bone disease,
or as a pharmaceutical. In particularly encompassed by the
invention is the use of an antibody that specifically recognizes
tenascin-W for the diagnosis of tumour, especially metastatic
tumour.
[0127] In a further embodiment, the present invention provides a
method for identifying agents for the prevention or the
prophylactic treatment of tumourigenesis or the treatment or
prophylactic treatment of tumours or cancer, or the treatment or
prophylactic treatment of any disease or condition involving
tenascin-W. e.g. a condition ameliorated by the promotion (or
inhibition) of osteogenesis, comprising contacting a test compound
with a tenascin-W expressing sample and then measuring a change in
one or more of (a) cell proliferation, e.g. cell progression
entering S-phase of the cell cycle; (b) DNA synthesis; (c) cell
adhesion; (d) cell spreading; (e) focal adhesion and actin stress
fibre formation on fibronectin; (f) cell binding to extracellular
matrix (ECM), relative to when said test compound is absent.
[0128] Cells may be encouraged to proliferate by the addition of
tenascin-W to the cell culture, preferably by coating the solid
substrate therewith. A substrate can be any surface that promotes
cell adhesion. The solid substrate may also be coated by other ECM
which include without limitation fibronectin, collagen, etc. The
cell cultures are preferably grown on a solid substrate or in a
liquid medium. A first measurement of one or more of (a) to (f) may
be made prior to contacting the cells with a test substance. A
second measurement may be made thereafter. A multiplicity of
further measurements may be made over a period of hours or days
after contact of the cells with the test compound. In this way a
time course of the cellular response(s) may be obtained and
analysed.
[0129] In one preferred embodiment of the present invention, the
presence of tenascin-W in the liquid medium is measured relative to
when a test compound is absent. An increase in the level of
tenascin-W present to the medium relative to when said test agent
is absent correlates to an agent effective in the promotion of
osteogenesis, for example. A decrease in the level of tenascin-W
present in the medium relative to when said test agent is absent
correlates to an anti-proliferative or anti-tumour agent, or an
agent effective in inhibiting osteogenesis or osteoblast
formation.
[0130] In preferred aspects one or more of the following conditions
arising after contacting cells with a test compound is indicative
of an anti-proliferative or anti-tumour agent, or an inhibitor of
osteoblast formation: [0131] (a) a reduction in cell proliferation;
or a decrease in the proportion of cells entering S-phase of the
cell cycle; [0132] (b) a reduction in DNA synthesis; [0133] (c) an
increase in cell adhesion; [0134] (d) an increase in cell
spreading; [0135] (e) an increase in focal adhesion and actin
stress fibre formation on fibronectin; and [0136] (f) an increase
in the binding of cells to ECM, preferably fibronectin;
[0137] In other preferred aspects one or more of the following
conditions arising after contacting cells with a test compound may
indicate an osteogenesis promoting agent: [0138] (a) an increase in
cell proliferation; or an increase in the proportion of cells
entering S-phase of the cell cycle; [0139] (b) an increase in DNA
synthesis; [0140] (c) and (d) an increase in the expression of
bone-specific markers such as alkaline phosphates activity,
calcification or any others known in the art (e.g., Raouf and Seth,
2002, Bone 30: 463-71).
[0141] Actin stress fibre formation may be assayed according to the
Actin Assembly Assay described in Bloom, I. et al (1999) Mol Biol
Cell 10: 1521-1536. Adhesion assays may be performed according to
the method described in Bloom, I. et al (1999).
[0142] In other embodiments, the method of the invention may
further comprise control cells grown in the absence of test
substance and (a), (b), (c), (d), (e), and/or (f) are measured in
both control and test cultures. The test measurements can thereby
be normalised with respect to the control.
[0143] The screening method further provides an essentially
cell-free system for the identification of potential anti-tumour or
tumor preventing agents or for an agent inhibiting osteogenesis.
This method relies on the ability of a potential anti-tumour agent
to prevent, inhibit or disrupt the binding between an ECM and
tenascin-W. The nature of any disruption of the ECM and tenascin-W
binding may be determined by performing a binding assay for ECM and
tenascin (see e.g. example 10). For example, calorimetric methods
may be used or measurement of labelled reagents.
[0144] Alternatively, a method is provided for identifying
modulators of tenascin W function, comprising: (a) contacting a
test compound with tenascin W and/or alpha8 beta1 integrin, and (b)
measuring the binding of the test compound to tenascin-W and/or
alpha8 beta1 integrin, or (c) measuring a disruption of binding of
tenascin-W to alpha8 beta1 integrin, relative to when the test
compound is absent. A decrease in binding of tenascin-W to alpha8
beta1 integrin is indicative of an inhibitor of this interaction,
and increased binding could indicated that the test compound
activates the alpha8 beta1 integrin, thereby increasing the
interaction between tenascin-W and alpha8 beta1.
[0145] The relative amounts or concentrations of reagents and test
substance may be varied, hereby permitting calculation of
inhibition constants and other parameters, e.g. binding affinities.
The optimisation of assay conditions will be well within the realm
of one of ordinary skill in the art. The system may further
comprise a control without test substance and the binding is
measured in the control, thereby permitting corresponding
measurements in the test system to be normalised relative to the
control.
[0146] Where one component of the assay (screening) systems of the
invention is coupled lo a solid particle or substrate, then one or
more of the other components not so coupled may be labelled.
Examples of labels include radio-labels e.g. .sup.14C or .sup.3H,
dyes, metal sols, enzymes or biotin/avidin. By attaching such
labels to "free" components in the system any binding assay may be
carried out in solution in accordance with procedures well known in
the art. After allowing the components to react solid phase
particles can be separated from solution, e.g. by filtration or
sedimentation (including centrifugation). In some embodiments
immunoprecipitation may be used to separate bound and free labelled
components. Usually, an antibody may be employed to bring an
unlabelled component out of solution (whether or not this component
has bound to another labelled component or not). After separation,
the label present in solution (free) and the label present in or on
the solid phase (bound) may be measured. Standard analyses of such
bound and free data, e.g. Scatchard plots and the determination of
affinity and inhibition constants for binding are well known to the
person of ordinary skill in the art.
[0147] Where the solid phase is not particulate, e.g. in the form
of a surface, such as a microfilter plate well, then binding assays
measuring bound and free label may be performed but this will
normally involve th removal of liquid phase from the wells after
binding reactions have occurred. Advantageously, this assay format
may dispense with the need for providing specifically labelled
reaction components. Instead, labelled antibodies may be used to
measure the binding of previously free reaction components to solid
phase components.
[0148] In some embodiments the tenascin-W molecule, variant or
fragment thereof may be attached directly to a solid phase. In
preferred immunoassay embodiments of this type, tenascin-W bound to
an ECM is measured using an antibody reactive against
tenascin-W.
[0149] Immunological binding assays are known in the art. For a
review, see Methods in Cell Biology Vol 37: Antibodies in Cell
Biology. Asai, (Ed.) Academic Press, Inc. New York (1993).
[0150] A label may be any detectable composition whereby the
detection can be spectroscopic, photochemical, biochemical,
immunochemical, physical or chemical. For example, useful labels
can include .sup.32P, .sup.35S, .sup.3H, .sup.14C, .sup.125I,
.sup.131I, fluorescent dyes (e.g. FITC, rhodamine and lanthanide
phosphors), electron-dense reagents, enzymes, e.g. as commonly used
in ELISA (e.g. horseradish peroxidase, beta-galactosidase,
luciferase and alkaline phosphatase), biotin, dioxigenin, or
haptens and proteins, for which antisera or monoclonal antibodies
are available. The label may be directly incorporated into a target
compound to be detected, or it may be attached to a probe or
antibody which binds to the target.
[0151] Throughout the assays of the invention, incubation and/or
washings steps may be required after each application of reagent or
incubation of combinations of reagents. Incubation steps may vary
from about 5 minutes to several hours, perhaps from about 30
minutes to about 6 hours. However, the incubation time usually
depends upon the assay format, analyte, volume of solution,
concentrations, and so forth. Usually, the assays should be carried
out at ambient temperature, although they may be conducted at
temperatures; in the range of 10.degree. C., to 40.degree. C., for
example.
[0152] A particularly preferred assay format is an enzyme-linked
immunosorbent assay (ELISA).
[0153] All of the aforementioned methods of screening of this
invention are equally applicable to the screening of substances for
biological activity and potential agents for any other disease or
condition involving tenascin-W, e.g. wound healing or treatment of
artherosclerosis.
[0154] Also included within the scope of the present invention are
anti-tumourigenic, anti-tumor, anti-metastatic, (anti-)osteogenic,
wound healing or anti-arthrosclerosis substances or substances for
the treatment or prophylatic treatment of any disease or condition
involving tenascin-W identified by any of the screening methods of
the invention. These substances may be proteins, polypeptides or
small organic molecules (drugs). The invention therefore includes
pharmaceutical compositions for preventing or treating tumours,
metastasis, or bone pathologies and comprising one or more of the
substances identified by a method of the invention. For example,
inhibitors of tenascin-W expression or activity are considered
potential anti-cancer agents, whereas tenascin W or agonists
thereof are considered agents effective in promoting osteogenesis,
which can be used in vivo or ex vivo.
[0155] Thus, the present invention provides a novel mammalian
member of the tenascin family and uses thereof. It permits the
identification of agents effective against conditions dependent on
tenascin-W, in particular anti-cancer agents or agents that promote
osteogenesis, by performance of any of the methods of screening
described herein. Preferred anti-cancer agents are those which
inhibit proliferation of the cancer cells and which may be general
anti-proliferative agents.
[0156] The invention includes all nucleic acid molecules and
proteins and polypeptides as hereinabove described, as well as
agents identified by performing the methods, and the use of these
agents as pharmaceuticals, particularly as medicaments for the
prophylaxis or treatment of cancer and other conditions dependent
on tenascin W.
[0157] Thus, in a further aspect the invention provides for the use
of tenascin-W and of an agent identified by a screening method or
the invention as a pharmaceutical.
[0158] The invention further provides tenascin-W or an agent
identified by a screening method of the invention, for the
manufacture of a medicament for the prophylaxis or treatment of a
condition dependent on tenascin-W, for use to treat cancer or bone
diseases or an immunological defect.
[0159] The invention provides a method of preventing or treating a
condition dependent on tenascin-W comprising administering to an
individual an effective amount of a construct, vector, host cell or
antibody described above.
[0160] The invention also provides a method of inhibiting a
condition dependent on tenascin-W comprising administering an
effective amount of the modulator identified by a screening method
of the invention described above, for the treatment of cancer or
bone disease or an immunological defect.
[0161] Also provided by the invention are the nucleic acid
molecules, the proteins, and the agents referred to above in a
pharmaceutical composition, possibly in the presence of suitable
exponents known to one of ordinary skill in the art. The
compositions may be administered in the form of any suitable
composition as detailed below by any suitable method of
administration within the knowledge of a skilled man. The preferred
route of administration is parentally. In parenteral
administration, the compositions of this invention will be
formulated in a unit dosage injectable form such as a solution,
suspension or emulsion, in association with a pharmaceutically
acceptable excipient. Such excipients are inherently nontoxic and
nontherapeutic. Examples of such excipients are saline. Ringers
solution, dextrose solution and Hank's solution. Nonaqueous
excipients such as fixed oils and ethyl oleate may also be used. A
preferred excipient is 5% dextrose in saline. The excipient may
contain minor amounts of additives such as substances that enhance
iso-tonicity and chemical slability, including buffers and
preservatives.
[0162] Any protein is administered al a concentration that is
therapeutically effective to prevent allograft rejection, GVHD,
allergy and autoimmune diseases. The dosage and mode of
administration will depend on the individual. Generally, the
compositions are administered so that the functional protein is
given at a dose between 1 pg/kg and 10 mg/kg, more preferably
between 10 ug/kg and 5 mg/kg, most preferably between 0.1 and 2
mg/kg. Preferably, it is given as a bolus dose. Continuous short
time infusion (during 30 minutes) may also be used. The
compositions according to the invention may be infused at a dose
between 5 and 20 .mu.g/kg/minute, more preferably between 7 and 15
ug/kg/minute.
[0163] According to a specific case, the "therapeutically effective
amount" of a composition needed should be determined as being the
amount sufficient to cure the patient in need to treatment or al
least to partially arrest the disease and its complications.
Amounts effective for such use will depend on the severity of the
disease and the general state of the patient's health. Single or
multiple administrations may be required depending on the dosage
and frequency as required and tolerated by the patient.
[0164] The present invention also provides a method of diagnosing
or prognosing cancer, or any other condition dependent on elevated
tenascin W levels, comprising, (a) analysing a sample obtained from
an individual for the presence of tenascin-W; and (b) correlating
the presence of tenascin-W with an unfavourable prognosis or
diagnosis.
[0165] The methods of the present invention will typically involve
the determination of the presence, level, or activity of tenascin-W
in a cell or tissue sample, which sample will often be obtained
from a human, but one can also readily understand that samples
tested by the present method can be obtained from agriculturally
important mammals, such as cattle, horses, sheep, etc., or other
animals of veterinary interest, such as cats and dogs. The assay
may be carried out on any cell or tissue sample, such as somatic
tissues, germiline tissues, or cancerous tissues, as well as on
samples from body fluids, such as pleural fluid, blood, serum,
plasma and urine. The method may also further comprise propagating
cells in the sample in cell culture.
[0166] A "sample"is the material being analyzed which is usually,
but not necessarily, subjected to pretreatment to provide the
tenascin-W in assayable from. This would for example, entail
forming a cell extract, methods for which are known in the art (for
example, see Scopes, Protein Purification: Principles and Practice,
Second Edition (Springer-Verlag, N.Y., 1987)).
[0167] In the broader aspects of the invention, there is no
limitation on the collection and handling of samples as long as
consistency is maintained. The sample is obtained by methods known
in the art, such as, biopsies, surgical resections, smears, or the
like. Optionally, cells obtained in a sample may be propagated in
cell culture.
[0168] Consistency of measurement of tenascin-W or tenascin-W
activity in clinical samples can be ensured by using a variety of
techniques. For example, to control for the quality of each tissue
extract, another enzymatic activity, such as alkaline phosphatase,
can serve as an internal control. In addition, an internal standard
can be measured concurrently with tenascin-W in the sample as a
control for assay conditions. Thus, the analyzing step can comprise
detecting a control protein in the sample, optionally normalizing
the value obtained for tenascin-W with a signal obtained with the
control protein.
[0169] The presence of tenascin-W in the sample can be determined
by detecting the tenascin-W protein using methods known in the art.
In this invention, there are no limitations on the type of assay
used to measure tenascin-W or tenascin-W activity. Tor example,
tenascin-W can be deflected by immunoassays using antibodies
specific for tenascin-W. The antibody can be used, for example, in
Western blots of two dimensional gels where the protein is
identified by enzyme linked immunoassay or in dot blot (Antibody
Sandwich) assays of total cellular protein, or partially purified
protein.
[0170] Methods for sample concentration and protein purification
are described in the literature (see Scopes, 1987). For example, if
desired, the tenascin-W present in the cell extract can be
concentrated, by precipitating with ammonium sulfate or by passing
the extract through a commercially available protein concentration
filter, e.g., an Amicon or Millipore, ultrafiltration unit. The
extract can be applied lo a suitable purification matrix, such as
an anion or a cation exchange resin, or a gel filtration matrix, or
subjected to preparative gel electrophoresis. In such cases, the
tenascin-W and protein yield after each purification step needs to
be considered in determining the amount of tenascin-W in a
sample.
[0171] Tenascin-W may be detected using an antibody specific for
tenascin-W, and a control assay can be carried out using an
antibody specific for another tenascin molecule. Optionally, the
method may further comprise correlating in an increase in
tenascin-W in the sample relative to healthy tissue. For example,
tenascin-W can be detected using an antibody specific for
tenascin-W expressed in tumour tissue and compared to antibody
binding to any tenascin-W expressed (or non-specific reaction) in
healthy tissue.
[0172] The sample is preferably a tissue sample mounted onto a
solid surface for histochemical analysis. The presence of
detectable, accessible tenascin-W indicates that tenascin-W is
accessible to cells for binding. This leads to a unfavourable
diagnosis or prognosis. If, on the other hand, the antibody does
not react with tenascin-W in the tissue section, then there is an
expectation that tenascin-W is not present. This leads to a
favourable diagnosis or prognosis.
[0173] The present inventors have found that tenascin-W is
specifically expressed in solid tumours, in particular metastatic
tumour tissue or siroma thereof. The presence of tenascin-W
therefore indicates a cancerous condition, in particular the
presence of metastatic tumour tissue, whereas the absence of
tenascin-W indicates healthy tissue or non-metastatic tumour
tissue. Tenascin-W was identified in developing mouse tissues by
western blotting. High expression of tenascin-W was found in the
metastatic tumours of non-metastatic tumours. The presence of
tenascin-W (170 kD) is indicative of unfavourable diagnosis.
[0174] In a further embodiment, the diagnostic and prognostic
methods of the invention further comprises analysing the sample for
the presence of alpha 8 integrin, the presence of alpha 8 integrin
correlating with an unfavourable prognosis or diagnosis. This can
easily be achieved, for example, using an antibody as described in
detail in Example 8 below.
[0175] In a preferred embodiment, the invention provides kits
suitable for use in the diagnostic or prognostic methods of the
invention. Such kits comprise reagents useful for carrying out
these methods, for example, antibodies from one or more species
specific for tenascin-W and alpha 8 beta1 integrin. Secondary
antibodies that recongnise either or both such primary
anti-fibronectin antibodies can also be included for the purpose of
recognition and detection of primary antibody binding to a sample.
Such secondary antibodies can be labelled for detection e.g. with
fluorophores, enzymes, radioactive labels or otherwise. Other
detection labels will occur to those skilled in the art.
Alternatively, the primary anti-tenascin-W antibodies can be
labelled for direct detection.
EXAMPLE 1
Cloning of Mouse Tenascin-W
[0176] Mouse tenascin-W was cloned from a cDNA library of 19d whole
mouse embryos (DupLEX-A DLM-110; OriGene Inc.). In a first step the
following PCR primers derived from a sequence from chromosome 1,
similar to Tenascin-R (Accession number AL049689) were used for
nested PCR reactions with the Expand High Fidelity PCR System
(Roche) using the mouse cDNA library as template. The first
reaction was performed with the primer set
5'-TAGCAGCCCACAGCATCTACTTGCC-3' (SEQ ID
NO:5)/5'-ATTGCTGTTCTGCTGAACCTGACTGCA-3' (SEQ ID NO:6) and the
second reaction with 5'-ATGGATCCAGAAATTGACGGCCCCAAAACCTAG-3' (SEQ
ID NO:7)/5'-ATAAGCTTGTGGAGAGGGTGGTGGATACATTTC-3' (SEQ ID NO:8). The
second primer set included a BamHI and a HindIII restriction site,
respectively, to allow the directed cloning into the bacterial
expression vector pQE30 (Qiagen) supplying a C-terminal His-tag for
the purification of the recombinant proteins.
[0177] The mouse proteins (tenascin W polypeptide fragments
obtained as a result of the above procedure) were expression in E.
coli and purified by a affinity chromatography to a Ni-NTA matrix
(Qiagen) according to the matrix supplier's manual. The protein was
purified under native conditions and was eluted with 250 mM
imidazole.
[0178] Full length tenascin-W was cloned by the use of mouse
tenascin-W specific primers derived from the above mouse tenascin-W
cDNA and primers matching the vector of the same 19d whole mouse
embryo cDNA library used before. To obtain the complete 5'
sequences, the following PCR reactions using the above cDNA as
template were performed: The first PCR reaction was performed using
the primer pair 5'-AGGAGATGGTGGCTGTATTTTCGG-3' (SEQ ID
NO:9)/5'-AGCCTCTTGCTGAGTGGAGATGCC-3' (SEQ ID NO:10) followed by a
second PCR reaction with the primer set
5TAGAATTCGGTCACCTGATTGGTCACTAGG-3' (SEQ ID
NO:1)/5'-TTATGATGTGCCAGATTATGCC-3' (SEQ ID NO:12). To complete the
3' part of the tenascin-W cDNA the following PCR reactions were
performed. In the first reaction the primer pair
5'-CTCAAAATTGATGGCTACATTTTGACC-3' (SEQ ID
NO:13)/5'-MGCCGACAACCTTGATTGGAGAC-3' (SEQ ID NO:14) was used
followed by the primer pair 5'-TACCAGTTCCCAAATGGCACCG-3' (SEQ ID
NO:15)/5'-AAACCTCTGGCGMGAAGTCC-3'(SEQ ID NO: 16). In each case the
longest products were cloned. These overlapping tenascin-W cDNA
clones were assembled into one full length mouse tenascin-W cDNA
and cloned into the expression vector pCEP/Pu (see Kohfeldt et al.
(1997).
[0179] FEBS I. eft. 414:557-61). At the 3' end of the tenascin-W
cDNA a 6.times.His-tag was inserted in front of the stop codon to
allow the purification of full length mouse tenascin-W protein
expressed in mammalian cell culture.
[0180] The recombinant mouse tenascin-W protein comprises three
C-terminal fibronectin type III repeats in the region defined by
amino acids 794-1057 of the complete amino acid sequence of mouse
tenascin-W, encoded by nucleotides 2380-3171 of the tenascin-W
nucleotide sequence.
EXAMPLE 2
Characterization of Mouse Tenascin-W
[0181] The full length cDNA of mouse tenascin-W was cloned as
described in example 1. The cDNA sequence encodes a typical member
of the tenascin protein family and harbors from the N-terminus to
the C-terminus of the protein the following structural domains:
signal peptide for secretion, N-terminal domain for dimerisation of
two tenascin-W trimers that are assembled by heptad repeats. This
results in a disulfide-linked hexameric protein complex where each
subunit contains three and a half EGF-like repeals, nine
fibronectin type III repeats, and a fibrinogen-like C-terminal
globular domain.
[0182] The full length tenascin-W cDNA was transfected into HEK 293
cells using the transaction reagent fugene (Roche). Transfected
cells were selected with puromycin and the medium containing the
secreted tenascin-W protein was collected and the protein was
purified by sequential chromatography over a gclatin-agarosc column
(Sigma) to remove any contaminating fibronectin in the preparation
and by adsorption to a Ni-NTA matrix (Qiagen). The tenascin-W was
eluted from the nickel column by 250 mM imidazole.
[0183] The recombinant protein was also analyzed by SDS-PAGE
(sodium dodecyl sulfate--polyacrytamide gel electrophoresis) on 6%
polyacrylamide gels, under reducing and non-reducing conditions as
well as by electron micros-copy after rotary shadowing using the
same procedure as described for tenascin-C (Chiquet-Ehrismann, R.
et al. (1988) Cell 53, 383-390). Tenascin-W showed a similarly slow
migration as the hexameric tenascin-C protein. Electronmicrographs
of tenascin-W after rotary shadowing indeed revealed hexameric
molecules with six subunits of about 50 nm length radiating from a
central globular domain.
EXAMPLE 3
Cloning of Human Tenascin-W
[0184] Human tenascin-W was cloned from cDNA made from mRNA
isolated from the osteosarcoma cell line Saos-2 (ATCC; HTB 85)
essentially as described in Example 1 using the same PCR primers.
The human protein was expressed and purified by affinity
chromatography to a Ni-NTA matrix (Qiagen) according to the matrix
suppliers manual. The protein was purified under native conditions
and was eluted with 250 mM imidazole.
[0185] The recombinant protein comprises the three C-terminal
fibronectin type III repeats in the region defined by amino acids
791-1054 of the complete amino acid sequence of human tenascin-W
encoded by nucleotides 2371-3163 of the tenascin-W nucleotide
sequence of the database entry AL049689), respectively.
[0186] Full length tenascin-W is cloned by the use of human
tenascin-W specific primers derived from the above human tenascin-W
cDNA and human genomic sequences 5' to the ATG start condon of the
cDNA sequence entry AL049689 using cDNA made from mRNA isolated
from osteoarcoma cell line Saos-2 (ATCC; HTB 85) as the template.
The following primers are used for three sets of nested PCRs:
TABLE-US-00001 hTNW1: 5'CATCCTGGAGGGTCTGCTCC3' (SEQ ID NO: 17)
hTNW2: 5'GGGCAATTGGTGTCAGCTTTC3' (SEQ ID NO: 18) hTNW3:
5'GACTCGAGCTTTCCAAGGATGAGTCTCC3' (SEQ ID NO: 19) hTNW4:
5'GAGGATCCCCTGGTTGCCCCTTTCAG3' (SEQ ID NO: 20) hTNW5:
5'GCGCTACACTTCTGCTGATG3' (SEQ ID NO: 21) hTNW6:
5'CTGTGGAGAGGGTGGTGG3' (SEQ ID NO: 22) hTNW7:
5'GACTCGAGTGCACAAGGATGAGAGCAG3' (SEQ ID NO: 23) hTNW8:
5'GAGGATCCACCCTTAAAGGCAACAAGGG3' (SEQ ID NO: 24) hTNW8:
5'GAGGATCCACCCTTAAAGGCAACAAGGG3' (SEQ ID NO: 24) hTNW9: P
5'CGCAGTCTGGTGGCATATTG3' (SEQ ID NO: 25) hTNW10:
5'CATGATTTGTTCTGCGGGC3' (SEQ ID NO: 26) hTNW11:
5'GACTCGAGCGGCTACATTCTGACTTACC3' (SEQ ID NO: 27) hThW12:
5'GAGGATCCTCAGTGATGGTGATGGTGATG3' (SEQ ID NO: 28)
[0187] The following PCR reactions are performed using for fragment
A primer combinations hTNW1/hTNW2 followed by hTNW3/hTNW4, for
fragment B htNW5/hTNW6 followed by hTNW7/hTNW8 and for fragment C
hTNW9/htNW10 followed by hTNW11/hTNW12. These three fragments can
be joined together to make up the full length human tenascin-W by
digesting fragment A with XhoI and AccI, fragment B with AccI/NarI
and fragment C with NarI/BamIII and cloning the ligated assembly
into the XhoI/BamHI sites or the expression vector pCEP/Pu (see
Kohfeldt et al. (1997) FEBS Lett. 414:557-61). At the 3'end of the
human tenascin-W cDNA a 6.times.His-tag was inserted in front of
the stop codon for ease of purification upon expression in
mammalian cell culture. Human tenascin-W is purified as described
for mouse tenascin-W (example 2).
EXAMPLE 4
Antibody Production, Immunohistochemistry and Immunoblots:
Expression of Tenascin-W During Development
[0188] The bacterially expressed recombinant fragment of mouse
tenascin-W as described above in Example 1, was used to raise
polyclonal antiserta in rabbits using standard immunization
procedures. These antisera were used to detect tenascin-W in tissue
extracts and cryosections of developing mouse embryos using methods
described for tenascin-Y (Hagios, C. et al. (1996) J. Cell Biol.
134, 1499-1512). The antiserum reacted specifically with purified
full-length recombinant tenascin-W as well as with endogenous
tenascin-W in tissue extracts of mouse organs, as demonstrated by
Western blotting. In both cases, tenascin-W was identified as a 170
kDa molecular weight species.
[0189] The anti-tenascin-W antiserum was used to investigate
tenascin-W expression during normal mouse development by
immunohistochemistry. For immunohistochemistry, tissues were fixed
in ice-cold 4% paraformaldehyde in phosphate-buffered saline (PBS)
overnight, washed with PBS and cryoprotected with 25% sucrose in
PBS overnight at 4.degree. C. The tissues were embedded in OCT
(Optimal Cutting Temperature) mounting medium (Cal. No. 27050 OCT
Compound by Ted Pella Inc., Calif.) and sections of 12-16 .mu.m
were cut and collected onto glass slides. The sections were
air-dried for 2 hours before staining with anti-tenascin-W
antiserum followed by a fluorescently labelled secondary
antibody.
[0190] Tenascin-W first appears at embryonic day 11.5 (E11.5) in
the maxillary process. Between: E14.5 and E16.5, tenascin-W and
tenascin-C expression overlaps in developing connective tissue
(palate and mandible) in the face and jaw. Furthermore tenascin-W
is found in the extracellular matrix (ECM) or smooth muscle,
mesothelia and bone. In the adult mouse tenascin-W is found in a
subset of the tenascin-C-positive ECM of the aortic valve and the
limbus. In these locations its expression coincides with the stem
cell compartment of the respective tissue. Tenascin-W is also
expressed in the periosteum, the stem cell compartment for
osteogenesis. Tenascin-W is also expressed in kidney and the
digestive tract in a subset of tenascin-C-positive regions, but not
in the brain.
EXAMPLE 5
Monoclonal Antibodies Against Human Tenascin-W
[0191] The bacterially expressed recombinant fragment of human
tenascin-W as described above in Example 3 was used to raise
monoclonal antibodies against human tenascin-W using standard
procedures. The monoclonal antibodies reacted specifically with
human tenascin-W having better building than relying on the
crossreactivity of the anti-mouse tenascin-W for human tenascin-W.
The monoclonal antibodies are particularly useful to stain human
tissues.
EXAMPLE 6
Tenascin-W Expression in Tumor Cells
[0192] Tenascin-W expression in tumour cells was tested and
compared with the known results for tenascin-C which has been found
to be highly expressed in tumour tissues (Chiquet-Ehrismann, R.
(1993) Sem. Cancer Biol. 4, 301-310). Mouse mammary tumours develop
readily in transgenic mice expressing oncogenes under the control
of mammary glad-specific promoters. Overexpression of c-myc results
in the growth of non-mestasatic tumours whereas overexpression of
11a-ras leads to the development of meta-static tumours (I.i, F. et
al. (1994) Int. J. Cancer 59, 560-568).
[0193] In this Example, the antisera described in Example 4 were
used to detect tenascin-W in mouse mammary tumours as described for
tenascin-Y by Hagios, C. et a., (1996). High expression of
tenascin-W (about 170 kDa) was found in the tumours of
res-transgenic mice (metastatic), but not in the mye- or
neuT-transformed non-metastatic tumours, whereas tenascin-C was
over-expressed in both types of tumours.
[0194] As a control, expression of tenascin-W was examined in
healthy tissue, using blood serum, for example. The content of
tenascin-W in serum is analyzed by Western blotting. For improved
sensitivity a Sandwich ELISA test as described previously for
tenascin-C (Schenk et al 1995. Int. J. Cancer 61:443-449) can be
used. Briefly, 96-well plates are coated with either polyclonal or
monoclonal anti-tenascin-W antibodies. The serum samples are
applied, the wells washed and the bound tenascin-W is detected by
either a polyclonal or a monoclonal anti-tenascin-W antibody
followed by an appropriate perioxidase-labeled secondary anti-body.
No expression of Tenascin-W was found in blood serum from wild-type
mice. In contrast, healthy kidney, heart valve and periosterum was
found to express Tenascin-W. Transgenic mice overexpressing neuT
develop non-metastasizing mammary tumours, whereas in transgenic
mice overexpressing neuT together with EphB4 receptor tyrosine
kinase the tumours are metasatic (Munarini, N, et al. (2002) Cell
Sci. 115, 25-37). Using this model system we again found high
expression of tenascin-W in mestastic tumours, but not in
non-metastatic ones. These expression patterns were confirmed by
SDS-PAGE (SDS-polyacrylamide gel electrophoresis), by fractionating
tumour extracts, blotting on polyvinylidene difluride membranes,
and analyzing the extract using anti-tenascin-W antisera.
EXAMPLE 7
Adhesion Assay
[0195] The purified tenascin-W was used for cell adhesion studies
of MDA-MB435 mammary carcinoma cells (ATTC; HTB-129), C2C12 mouse
skeletal myoblasts (AITC; CRL-1772, T98G glioblastoma cells (AITC;
CRI.-1690) and NIH-3T3 fibroblasts (ATTC; CRI.-1658). In brief,
60-well microliter plates (Nunc) were coated with 2-100 .mu.g/ml
tenascin-W for 1 h at 37.degree. C. The non-coated plastic surface
was blocked with 1% heat-inactivated BSA in PHS.
[0196] Cells were trypsinised, trypsin was blocked with 100
.mu.g/ml soybean trypsin inhibitor in PBS and, cells were
resuspended in serum-free medium and counted 200-500 cells per well
were plated for the indicated time points, fixed by addition of
glutaraldehyde (2% final concentration) for 15 minutes and stained
with 0.1% crystalviolet in 20% methanol for 30 minutes. Cells were
observed under a microscope (Nikon diaphot).
[0197] Most cells adhered to tenascin-W cooled at 2-100 .mu.g,
whereas cell adhesion to tenascin-C was minimal.
[0198] We compared the morphology and actin cytoskeleton of C2C12
mouse skeletal myoblasts and T98G glioblastoma plated on tenascin-W
to cells plated on fibronectin or tenascin-C. The shape of the
cells on tenascin-W was very different from the cells on
fibronectin, which became particularly evident after F-actin
staining with phalloidin. The cells on fibronectin were well spread
containing stress fibers, whereas the cells on tenascin-W had many
actin-rich processes but no stress fibers and the cell bodies
remained relatively round.
EXAMPLE 8
Identification of a Cellular Tenascin-W Receptor
[0199] To determine the cellular receptor(s) responsible for cell
adhesion to tenascin-W we tested the effect of integrin
function-blocking antibodies on adhesion of T98G glyoblasloma cells
on tenascin-W. Antibodies to .alpha.1, .alpha.2, .alpha.3,
.alpha.4, .alpha.5, .alpha.6 and .alpha.V were unable to inhibit
adhesion of T98G cells to tenascin-W. Nevertheless. this adhesion
was .beta.1 integrin-depended since 10 .mu.g/ml of the anti-.beta.1
integrin blocking antibody P4C10 (Sigma) was able to completely
inhibit adhesion to tenascin-W.
[0200] IDG tripeptidc motifs have been reported be the recognition
sequence for alpha9 beta1 integin (Yokosakt et al., 1998). Since
mouse tenascin-W contains three IDG motifs we investigated whether
.alpha.9 integrin could be the receptor for tenascin-W. We plated
SW480 colon carcinoma cells transfected either with an empty vector
or with the vector containing the cDNA for .alpha.9 integrin
(Yokosakt et al. J Biol. Chem. 1996 Sep. 27;271(39):24144-50) on
tenascin-W coated wells. However, the .alpha.9-and mock-transfected
SW480 cells failed to adhere top tenascin-W whereas they adhered
well to fibronectin and collagen.
[0201] Integrin .alpha.8 is expressed in developing rib bone, in
kidney and in smooth muscle from the gastrointestinal tract (Denda
et al. Biochemistry. 1998 Apr. 21;37(16):5464-74). Since this
expression pattern coincides with the presence of tenascin-W it
seemed that integrin .alpha.8 was a good candidate receptor for
tenascin-W as well. We tested this hypothesis by using the leukemia
cell line K562, transfected with .alpha.8 integrin (Denda et al.
Biochemistry. 1998 Apr. 21;37(16):5464-74). Transfected K562 cells
could indeed adhere to tenascin-W and the mock-transfected control
cells did not. Therefore, .alpha.8.beta.1 integrin is a receptor
for tenascin-W.
EXAMPLE 9
DNA Replication and Publication Assay
[0202] 96-well plates (Falcon) are coated as described above. Cells
are serum starved overnight and trypainised. 10.sup.4 cells are
transferred onto the coated plates in the presence of 1% serum or
40 nM PDGF BB (Platelet-derived growth factor BB). 14 h later cells
are labelled with radioactive .sup.3H-thymidine (0.5 .mu.Ci/well)
for 4 h at 37.degree. C., incorporated .sup.3H-thymidine
precipitated with 10% TCA and determined with a Beckman
scintillation counter after cell lysis in 0.3N NaOH, 2% SDS.
Alternatively, incorporation of BrdU is measured or cells numbers
are counted over a growth period of several days of cells plated on
different substrates. Cancer cells grown on tenascin-W show an
increased growth rate over cells plated on fibronectin, as
established by counting cells or an increase in radioactive
.sup.3H-thymidine or BrdU incorporation into cellular RNA.
EXAMPLE 10
In Vitro Binding Assay (EUSA)
[0203] 96-well ELISA plates are coated with the appropriate ECM
proteins (e.g. fibronectin or tenascin-W) for 1 h at 37.degree. C.,
blocked with 1% milkpowder, 0.05% Tween-20 in PBS ECM protein
(tenascin-W or fibronectin) are added in blocking solution for 1 h,
washed with blocking solution and the appropriate antibodies are
added. In this way, an intersection between tenascin-W and
fibronectin can be tested, for example. Bound proteins are detected
by immune reaction with a peroxidase-coupled secondary antibody
followed by colour reaction with 21 mg/ml citric and 1-hydrate, 34
mg/ml Na.sub.2HPO.sub.42H.sub.2O, 0.4 mg/ml phenylenediamine, 1
.mu.l H.sub.2O.sub.2, which can be stopped with 4M sulphuric acid.
The absorbance was read at 590 nm.
EXAMPLE 11
Immunofluorescence Microscopy
[0204] 10.sup.4 cells are transferred onto 4-well Cellstar plastic
plates (Greiner) that are coated with ECM proteins essentially as
described above. Cells are fixed with 4% paraformaldehyde, 50 mM
phosphate buffer, 5 mM EDTA in PBS for 15 minutes, blocked with 3%
BSA, 0.5% Tween-20 in PBS and incubated with primary and secondary
antibodies in blocking solution. Slides are embedded in 10.5%
Mowiol containing 2.5% DABCO as antifade agent. Cells are analysed
by microscopy. This method is particularly useful for the detection
of tenascin-W or any other protein produced by cells in culture to
which an antibody is available and can be used to analyze
substances that affect the synthesis or deposition of the
respective antigens.
[0205] As is apparent to one of ordinary skill in the art,
variations in the above-described methods can be introduced with
case to attain the same objective. Various incubating conditions,
labels, apparatus and materials can be chosen according to
individual preference. All publications referred to herein are
incorporated by reference in their entirety as if each were
referred so individually.
Sequence CWU 1
1
2813891DNAMus musculusCDS(1)...(3891)Mouse tenascin-W 1atg ggt ctc
tgg ggg atg ctc gcc ttc ccc ctg gga ttt ctg ctt gct 48Met Gly Leu
Trp Gly Met Leu Ala Phe Pro Leu Gly Phe Leu Leu Ala 1 5 10 15tct
gtg ctc ctg gtg gct tcg gcc cca gcc act cca gag tct ccc ggc 96Ser
Val Leu Leu Val Ala Ser Ala Pro Ala Thr Pro Glu Ser Pro Gly 20 25
30tgc agc aac aaa gag caa cag gtc act gtt agc cac acc tac aag att
144Cys Ser Asn Lys Glu Gln Gln Val Thr Val Ser His Thr Tyr Lys Ile
35 40 45gac gtg ccc aag tct gct ctg gtt caa gta gag acc gac cca cag
tca 192Asp Val Pro Lys Ser Ala Leu Val Gln Val Glu Thr Asp Pro Gln
Ser 50 55 60ctc agc gat gat ggg aca tca ctc ttg gct ccc ggg gag gat
ggg gag 240Leu Ser Asp Asp Gly Thr Ser Leu Leu Ala Pro Gly Glu Asp
Gly Glu 65 70 75 80gag cag aac att atc ttc agg cac aac atc cgt ctt
cag aca ccg cag 288Glu Gln Asn Ile Ile Phe Arg His Asn Ile Arg Leu
Gln Thr Pro Gln 85 90 95aag aat tgc gac ctg gca gac agt gtc cag gac
ctg cta gcc cgg atg 336Lys Asn Cys Asp Leu Ala Asp Ser Val Gln Asp
Leu Leu Ala Arg Met 100 105 110aaa aag ctg gag gaa gag atg gca gag
ctg aag gag cag tgc aat acc 384Lys Lys Leu Glu Glu Glu Met Ala Glu
Leu Lys Glu Gln Cys Asn Thr 115 120 125aac cgc tgc tgc cag ggg gct
gct gat ctg agc cgt cac tgc agt ggc 432Asn Arg Cys Cys Gln Gly Ala
Ala Asp Leu Ser Arg His Cys Ser Gly 130 135 140cac ggg acc ttc ctc
cct gag acc tgc agc tgc cac tgt gac cag ggc 480His Gly Thr Phe Leu
Pro Glu Thr Cys Ser Cys His Cys Asp Gln Gly145 150 155 160tgg gag
ggc gca gac tgt gat cag ccc acc tgt cct ggg gct tgc aac 528Trp Glu
Gly Ala Asp Cys Asp Gln Pro Thr Cys Pro Gly Ala Cys Asn 165 170
175ggc cac ggg cgc tgt gtg gat ggg cag tgc gtg tgt gac gcg ccc tat
576Gly His Gly Arg Cys Val Asp Gly Gln Cys Val Cys Asp Ala Pro Tyr
180 185 190gtg ggg gtc gac tgc gcc tac gcc gcc tgt ccc cag gac tgc
agt ggg 624Val Gly Val Asp Cys Ala Tyr Ala Ala Cys Pro Gln Asp Cys
Ser Gly 195 200 205cat ggc gtg tgc gtg cag ggt gtc tgc cag tgc cac
gag gac ttc aca 672His Gly Val Cys Val Gln Gly Val Cys Gln Cys His
Glu Asp Phe Thr 210 215 220gca gag gac tgc agc gag cag cgc tgt cct
ggc gac tgt agt ggc aat 720Ala Glu Asp Cys Ser Glu Gln Arg Cys Pro
Gly Asp Cys Ser Gly Asn225 230 235 240ggt ttc tgt gac act ggc gag
tgt tac tgt gag atg ggc ttt act ggc 768Gly Phe Cys Asp Thr Gly Glu
Cys Tyr Cys Glu Met Gly Phe Thr Gly 245 250 255ccc gac tgt tcc cag
gtg gtg gct cct cag ggc ctg cag ttg ctc aag 816Pro Asp Cys Ser Gln
Val Val Ala Pro Gln Gly Leu Gln Leu Leu Lys 260 265 270agc acg gag
aac tct ctg ctg gtg agt tgg gag ccc tcc agt gag gta 864Ser Thr Glu
Asn Ser Leu Leu Val Ser Trp Glu Pro Ser Ser Glu Val 275 280 285gac
tac tac ctg ctc agc tac tac ccc ctg ggg aag gag caa gct aca 912Asp
Tyr Tyr Leu Leu Ser Tyr Tyr Pro Leu Gly Lys Glu Gln Ala Thr 290 295
300aaa cag gtc cgg gta ccc aag gag cag cac acc tat gac atc acc ggc
960Lys Gln Val Arg Val Pro Lys Glu Gln His Thr Tyr Asp Ile Thr
Gly305 310 315 320ttg ctg cct gga acc aag tac ata gtc acc ctg cgc
aac gtg aag aaa 1008Leu Leu Pro Gly Thr Lys Tyr Ile Val Thr Leu Arg
Asn Val Lys Lys 325 330 335gac att tcc agc agc cct cag cat cta ctt
gcc acc aca gac ctt gct 1056Asp Ile Ser Ser Ser Pro Gln His Leu Leu
Ala Thr Thr Asp Leu Ala 340 345 350gtg ctt ggc act gcc tgg gta aat
gaa gag act gag aca tcc ctc gat 1104Val Leu Gly Thr Ala Trp Val Asn
Glu Glu Thr Glu Thr Ser Leu Asp 355 360 365gtg gag tgg gag aac cct
ctg act gag gtg gac tat tac aag ctt cgg 1152Val Glu Trp Glu Asn Pro
Leu Thr Glu Val Asp Tyr Tyr Lys Leu Arg 370 375 380tat ggc ccc tta
aca ggg cag gag gtg aca gag gtc act gtg ccc aag 1200Tyr Gly Pro Leu
Thr Gly Gln Glu Val Thr Glu Val Thr Val Pro Lys385 390 395 400agc
cgt gat ccc aag agc aga tat gac atc act ggt ctg cag cct gga 1248Ser
Arg Asp Pro Lys Ser Arg Tyr Asp Ile Thr Gly Leu Gln Pro Gly 405 410
415acg gaa tat aaa atc aca gtt gtg ccc atc cga ggt gat ctg gag gga
1296Thr Glu Tyr Lys Ile Thr Val Val Pro Ile Arg Gly Asp Leu Glu Gly
420 425 430aag ccg att ctc ctg aat ggc agg aca gaa att gat gga cca
acc aat 1344Lys Pro Ile Leu Leu Asn Gly Arg Thr Glu Ile Asp Gly Pro
Thr Asn 435 440 445gtg gtc aca aat cag gtg aca gaa gac aca gca tct
gtt tcc tgg gat 1392Val Val Thr Asn Gln Val Thr Glu Asp Thr Ala Ser
Val Ser Trp Asp 450 455 460cca gtg agg gct gac ata gac aag tat gtg
gtg cgc tat atc gcc ccc 1440Pro Val Arg Ala Asp Ile Asp Lys Tyr Val
Val Arg Tyr Ile Ala Pro465 470 475 480gat ggg gag acc aag gag aag
gca gta cca aag gac cag agc agc acc 1488Asp Gly Glu Thr Lys Glu Lys
Ala Val Pro Lys Asp Gln Ser Ser Thr 485 490 495gtt ctc aca ggc ctg
aag cca gga gag gcc tac aaa gtc ttt gtg tgg 1536Val Leu Thr Gly Leu
Lys Pro Gly Glu Ala Tyr Lys Val Phe Val Trp 500 505 510gct gag agg
ggc aac caa ggc agc aag aaa gca gac acc aag gcc ctc 1584Ala Glu Arg
Gly Asn Gln Gly Ser Lys Lys Ala Asp Thr Lys Ala Leu 515 520 525aca
gaa att gac agt cca gaa aac ctg gtg act gac cgg gtg aca gag 1632Thr
Glu Ile Asp Ser Pro Glu Asn Leu Val Thr Asp Arg Val Thr Glu 530 535
540aac agc ctc tct gtc tcg tgg gac cca gtg gag gct gac atc gac agg
1680Asn Ser Leu Ser Val Ser Trp Asp Pro Val Glu Ala Asp Ile Asp
Arg545 550 555 560tat gtg gta agc tac act tcc gtg gat gga gag acg
aag cag gtt cca 1728Tyr Val Val Ser Tyr Thr Ser Val Asp Gly Glu Thr
Lys Gln Val Pro 565 570 575gtg aag aag gac cag agg agc acc gtc ctc
acc ggc ctg agt ccc ggt 1776Val Lys Lys Asp Gln Arg Ser Thr Val Leu
Thr Gly Leu Ser Pro Gly 580 585 590gtg gag tac aaa gtt tac gtg tgg
gca gag aaa ggc gat cgg gag agc 1824Val Glu Tyr Lys Val Tyr Val Trp
Ala Glu Lys Gly Asp Arg Glu Ser 595 600 605aag aag gcc aac acc aag
gct ccc aca gac atc gac agc ccc aaa aac 1872Lys Lys Ala Asn Thr Lys
Ala Pro Thr Asp Ile Asp Ser Pro Lys Asn 610 615 620ttg gta act gac
cag gtg aca gag aac act ctc agt gtc tcc tgg gac 1920Leu Val Thr Asp
Gln Val Thr Glu Asn Thr Leu Ser Val Ser Trp Asp625 630 635 640cct
gtt cag gcc aac att gac agg tat atg gtg agc tac acc tct gcc 1968Pro
Val Gln Ala Asn Ile Asp Arg Tyr Met Val Ser Tyr Thr Ser Ala 645 650
655gat gga gag aca aga gag gtc cca gtg cct aag gag aag agc agt acc
2016Asp Gly Glu Thr Arg Glu Val Pro Val Pro Lys Glu Lys Ser Ser Thr
660 665 670gtc ctg act ggc ctg agg cca ggt gtg gag tac aag gtc cat
gtg tgg 2064Val Leu Thr Gly Leu Arg Pro Gly Val Glu Tyr Lys Val His
Val Trp 675 680 685gcc cag aag ggg acc cag gag agc aga aag gcc aac
acc aag gcc ccc 2112Ala Gln Lys Gly Thr Gln Glu Ser Arg Lys Ala Asn
Thr Lys Ala Pro 690 695 700aca gat att gat ggc ccc aaa aac ctg gtg
act gac cag gtg acc gag 2160Thr Asp Ile Asp Gly Pro Lys Asn Leu Val
Thr Asp Gln Val Thr Glu705 710 715 720acc act ctt agt gtc tcc tgg
gac cca gtg gag gct gac att gat agg 2208Thr Thr Leu Ser Val Ser Trp
Asp Pro Val Glu Ala Asp Ile Asp Arg 725 730 735tac atg gtt cgc tac
acg tct cct gat gga gag acc aag gag gtg cct 2256Tyr Met Val Arg Tyr
Thr Ser Pro Asp Gly Glu Thr Lys Glu Val Pro 740 745 750gtg tca aag
gat aag agc agc aca gtc ctg agg ggc ctg agg cca ggt 2304Val Ser Lys
Asp Lys Ser Ser Thr Val Leu Arg Gly Leu Arg Pro Gly 755 760 765gtg
gag tac aag gtg gat gta tgg gcc cag aag ggg gcc cag gac agc 2352Val
Glu Tyr Lys Val Asp Val Trp Ala Gln Lys Gly Ala Gln Asp Ser 770 775
780cgg aag gcc aac acc aag gcc ccc aca gat att gac agc cct aaa aac
2400Arg Lys Ala Asn Thr Lys Ala Pro Thr Asp Ile Asp Ser Pro Lys
Asn785 790 795 800cta gtg act gag cag gtg gca gag agc act gcc acc
gtg tcc tgg gac 2448Leu Val Thr Glu Gln Val Ala Glu Ser Thr Ala Thr
Val Ser Trp Asp 805 810 815cca gta gag gct gac atc gac agg tat gtg
gtg cgc tac acc tct gct 2496Pro Val Glu Ala Asp Ile Asp Arg Tyr Val
Val Arg Tyr Thr Ser Ala 820 825 830gat gga gag acc agg gag att cca
gtg agg aag gag aag agc agc act 2544Asp Gly Glu Thr Arg Glu Ile Pro
Val Arg Lys Glu Lys Ser Ser Thr 835 840 845gtc ctc aca ggc ctg aga
ccg ggt gtg gag tac acg gtc caa gtg tgg 2592Val Leu Thr Gly Leu Arg
Pro Gly Val Glu Tyr Thr Val Gln Val Trp 850 855 860gct cag aag ggg
gcc cgg gag agc aag aag gcc aaa acc aag gcc ccc 2640Ala Gln Lys Gly
Ala Arg Glu Ser Lys Lys Ala Lys Thr Lys Ala Pro865 870 875 880aca
gaa att gac agc ccc aag aac ttg gtg acc aac cga gtg aca gaa 2688Thr
Glu Ile Asp Ser Pro Lys Asn Leu Val Thr Asn Arg Val Thr Glu 885 890
895aat aca gcc acc atc tcc tgg gac cca gtg cga gcc aac att gac agg
2736Asn Thr Ala Thr Ile Ser Trp Asp Pro Val Arg Ala Asn Ile Asp Arg
900 905 910tac atg gtt cgc tac acc tct gcg gat gga gag act aag gag
att cca 2784Tyr Met Val Arg Tyr Thr Ser Ala Asp Gly Glu Thr Lys Glu
Ile Pro 915 920 925gtg tca aag gat cag agt aac acc atc ctg aca ggc
ctg aaa cca ggc 2832Val Ser Lys Asp Gln Ser Asn Thr Ile Leu Thr Gly
Leu Lys Pro Gly 930 935 940atg gaa tat acc att cat gtg tgg gcc cag
aag ggg gcc cgg gag agc 2880Met Glu Tyr Thr Ile His Val Trp Ala Gln
Lys Gly Ala Arg Glu Ser945 950 955 960aag aag gct gat acc aag gcc
cta aca gaa att gac cct ccc aga aat 2928Lys Lys Ala Asp Thr Lys Ala
Leu Thr Glu Ile Asp Pro Pro Arg Asn 965 970 975ctc cgt ccg ttc ggg
gta aca cat tct ggt ggg gtt ttg acc tgg ttg 2976Leu Arg Pro Phe Gly
Val Thr His Ser Gly Gly Val Leu Thr Trp Leu 980 985 990ccc cca tct
gct caa att gat ggc tac att ttg acc tac cag ttc cca 3024Pro Pro Ser
Ala Gln Ile Asp Gly Tyr Ile Leu Thr Tyr Gln Phe Pro 995 1000
1005aat ggc acc gtg aag ggg gtg gag ctc cca aga ggc cag cag aga ttt
3072Asn Gly Thr Val Lys Gly Val Glu Leu Pro Arg Gly Gln Gln Arg Phe
1010 1015 1020gaa ttg caa gac ctg gaa cag ggt gtc acc tat cct gtt
tcc ttg gtt 3120Glu Leu Gln Asp Leu Glu Gln Gly Val Thr Tyr Pro Val
Ser Leu Val1025 1030 1035 1040gcc ttc aaa ggt aat cag cgg agc cgg
act gtg tct acc acc ctt tct 3168Ala Phe Lys Gly Asn Gln Arg Ser Arg
Thr Val Ser Thr Thr Leu Ser 1045 1050 1055aca gtg gat gct cgc ttt
cca cac ccc tca gac tgc agt caa gtt cag 3216Thr Val Asp Ala Arg Phe
Pro His Pro Ser Asp Cys Ser Gln Val Gln 1060 1065 1070cag aac acc
aac gct gcc agt ggg ctc tac acc atc tac ctc aat ggt 3264Gln Asn Thr
Asn Ala Ala Ser Gly Leu Tyr Thr Ile Tyr Leu Asn Gly 1075 1080
1085gat gcc agc cgg ccc atg cag gtg tac tgc gac atg gac act gac gga
3312Asp Ala Ser Arg Pro Met Gln Val Tyr Cys Asp Met Asp Thr Asp Gly
1090 1095 1100ggc ggc tgg att gtc ttc cag aga cgg aac act ggg cag
ctg gat ttc 3360Gly Gly Trp Ile Val Phe Gln Arg Arg Asn Thr Gly Gln
Leu Asp Phe1105 1110 1115 1120ttc aag cgt tgg cgg agt tat gta gaa
ggt ttt ggg gac ccc atg aag 3408Phe Lys Arg Trp Arg Ser Tyr Val Glu
Gly Phe Gly Asp Pro Met Lys 1125 1130 1135gag ttc tgg ctt gga ctt
gat aaa cta cat aat ctc acc act ggc acc 3456Glu Phe Trp Leu Gly Leu
Asp Lys Leu His Asn Leu Thr Thr Gly Thr 1140 1145 1150acc act cgg
tat gag gtg agg gca gac tta cag act ttc aat gaa tct 3504Thr Thr Arg
Tyr Glu Val Arg Ala Asp Leu Gln Thr Phe Asn Glu Ser 1155 1160
1165gcc tac gct gta tat gat ttc ttc caa gtg gca tcc agc aaa gag cgg
3552Ala Tyr Ala Val Tyr Asp Phe Phe Gln Val Ala Ser Ser Lys Glu Arg
1170 1175 1180tac aag ctg tcg gtt ggg aaa tac aga ggc aca gcc ggg
gat gct ctc 3600Tyr Lys Leu Ser Val Gly Lys Tyr Arg Gly Thr Ala Gly
Asp Ala Leu1185 1190 1195 1200acc tac cac aat gga tgg aag ttc acg
act ttt gac aga gac agt gat 3648Thr Tyr His Asn Gly Trp Lys Phe Thr
Thr Phe Asp Arg Asp Ser Asp 1205 1210 1215att gcc ctc agc aac tgt
gca ctg acg cat cat ggt ggc tgg tgg tat 3696Ile Ala Leu Ser Asn Cys
Ala Leu Thr His His Gly Gly Trp Trp Tyr 1220 1225 1230aag aac tgc
cat ttg gcc aac ccg aat ggc aaa tat ggg gag acc aag 3744Lys Asn Cys
His Leu Ala Asn Pro Asn Gly Lys Tyr Gly Glu Thr Lys 1235 1240
1245cac agc gag ggg gtg aac tgg gag cca tgg aag gga cat gag ttc tcc
3792His Ser Glu Gly Val Asn Trp Glu Pro Trp Lys Gly His Glu Phe Ser
1250 1255 1260att cct tat gtg gag ctg aaa atc cgc ccg ttt ggt tac
agc aga gac 3840Ile Pro Tyr Val Glu Leu Lys Ile Arg Pro Phe Gly Tyr
Ser Arg Asp1265 1270 1275 1280cgt ttc tct ggc aga aag aag cgc tcc
ata gga aaa gca agg atg ttc 3888Arg Phe Ser Gly Arg Lys Lys Arg Ser
Ile Gly Lys Ala Arg Met Phe 1285 1290 1295tga 3891*21296PRTMus
musculus 2Met Gly Leu Trp Gly Met Leu Ala Phe Pro Leu Gly Phe Leu
Leu Ala 1 5 10 15Ser Val Leu Leu Val Ala Ser Ala Pro Ala Thr Pro
Glu Ser Pro Gly 20 25 30Cys Ser Asn Lys Glu Gln Gln Val Thr Val Ser
His Thr Tyr Lys Ile 35 40 45Asp Val Pro Lys Ser Ala Leu Val Gln Val
Glu Thr Asp Pro Gln Ser 50 55 60Leu Ser Asp Asp Gly Thr Ser Leu Leu
Ala Pro Gly Glu Asp Gly Glu65 70 75 80Glu Gln Asn Ile Ile Phe Arg
His Asn Ile Arg Leu Gln Thr Pro Gln 85 90 95Lys Asn Cys Asp Leu Ala
Asp Ser Val Gln Asp Leu Leu Ala Arg Met 100 105 110Lys Lys Leu Glu
Glu Glu Met Ala Glu Leu Lys Glu Gln Cys Asn Thr 115 120 125Asn Arg
Cys Cys Gln Gly Ala Ala Asp Leu Ser Arg His Cys Ser Gly 130 135
140His Gly Thr Phe Leu Pro Glu Thr Cys Ser Cys His Cys Asp Gln
Gly145 150 155 160Trp Glu Gly Ala Asp Cys Asp Gln Pro Thr Cys Pro
Gly Ala Cys Asn 165 170 175Gly His Gly Arg Cys Val Asp Gly Gln Cys
Val Cys Asp Ala Pro Tyr 180 185 190Val Gly Val Asp Cys Ala Tyr Ala
Ala Cys Pro Gln Asp Cys Ser Gly 195 200 205His Gly Val Cys Val Gln
Gly Val Cys Gln Cys His Glu Asp Phe Thr 210 215 220Ala Glu Asp Cys
Ser Glu Gln Arg Cys Pro Gly Asp Cys Ser Gly Asn225 230 235 240Gly
Phe Cys Asp Thr Gly Glu Cys Tyr Cys Glu Met Gly Phe Thr Gly 245 250
255Pro Asp Cys Ser Gln Val Val Ala Pro Gln Gly Leu Gln Leu Leu Lys
260 265 270Ser Thr Glu Asn Ser Leu Leu Val Ser Trp Glu Pro Ser Ser
Glu Val 275 280 285Asp Tyr Tyr Leu Leu Ser Tyr Tyr Pro Leu Gly Lys
Glu Gln Ala Thr 290 295 300Lys Gln Val Arg Val Pro Lys Glu Gln His
Thr Tyr Asp Ile Thr Gly305 310 315 320Leu Leu Pro Gly Thr Lys Tyr
Ile Val Thr Leu Arg Asn Val Lys Lys 325 330 335Asp Ile Ser Ser Ser
Pro Gln His Leu Leu Ala Thr Thr Asp Leu Ala 340 345 350Val Leu Gly
Thr Ala Trp Val Asn Glu Glu Thr Glu Thr Ser Leu Asp 355 360 365Val
Glu Trp Glu Asn Pro Leu
Thr Glu Val Asp Tyr Tyr Lys Leu Arg 370 375 380Tyr Gly Pro Leu Thr
Gly Gln Glu Val Thr Glu Val Thr Val Pro Lys385 390 395 400Ser Arg
Asp Pro Lys Ser Arg Tyr Asp Ile Thr Gly Leu Gln Pro Gly 405 410
415Thr Glu Tyr Lys Ile Thr Val Val Pro Ile Arg Gly Asp Leu Glu Gly
420 425 430Lys Pro Ile Leu Leu Asn Gly Arg Thr Glu Ile Asp Gly Pro
Thr Asn 435 440 445Val Val Thr Asn Gln Val Thr Glu Asp Thr Ala Ser
Val Ser Trp Asp 450 455 460Pro Val Arg Ala Asp Ile Asp Lys Tyr Val
Val Arg Tyr Ile Ala Pro465 470 475 480Asp Gly Glu Thr Lys Glu Lys
Ala Val Pro Lys Asp Gln Ser Ser Thr 485 490 495Val Leu Thr Gly Leu
Lys Pro Gly Glu Ala Tyr Lys Val Phe Val Trp 500 505 510Ala Glu Arg
Gly Asn Gln Gly Ser Lys Lys Ala Asp Thr Lys Ala Leu 515 520 525Thr
Glu Ile Asp Ser Pro Glu Asn Leu Val Thr Asp Arg Val Thr Glu 530 535
540Asn Ser Leu Ser Val Ser Trp Asp Pro Val Glu Ala Asp Ile Asp
Arg545 550 555 560Tyr Val Val Ser Tyr Thr Ser Val Asp Gly Glu Thr
Lys Gln Val Pro 565 570 575Val Lys Lys Asp Gln Arg Ser Thr Val Leu
Thr Gly Leu Ser Pro Gly 580 585 590Val Glu Tyr Lys Val Tyr Val Trp
Ala Glu Lys Gly Asp Arg Glu Ser 595 600 605Lys Lys Ala Asn Thr Lys
Ala Pro Thr Asp Ile Asp Ser Pro Lys Asn 610 615 620Leu Val Thr Asp
Gln Val Thr Glu Asn Thr Leu Ser Val Ser Trp Asp625 630 635 640Pro
Val Gln Ala Asn Ile Asp Arg Tyr Met Val Ser Tyr Thr Ser Ala 645 650
655Asp Gly Glu Thr Arg Glu Val Pro Val Pro Lys Glu Lys Ser Ser Thr
660 665 670Val Leu Thr Gly Leu Arg Pro Gly Val Glu Tyr Lys Val His
Val Trp 675 680 685Ala Gln Lys Gly Thr Gln Glu Ser Arg Lys Ala Asn
Thr Lys Ala Pro 690 695 700Thr Asp Ile Asp Gly Pro Lys Asn Leu Val
Thr Asp Gln Val Thr Glu705 710 715 720Thr Thr Leu Ser Val Ser Trp
Asp Pro Val Glu Ala Asp Ile Asp Arg 725 730 735Tyr Met Val Arg Tyr
Thr Ser Pro Asp Gly Glu Thr Lys Glu Val Pro 740 745 750Val Ser Lys
Asp Lys Ser Ser Thr Val Leu Arg Gly Leu Arg Pro Gly 755 760 765Val
Glu Tyr Lys Val Asp Val Trp Ala Gln Lys Gly Ala Gln Asp Ser 770 775
780Arg Lys Ala Asn Thr Lys Ala Pro Thr Asp Ile Asp Ser Pro Lys
Asn785 790 795 800Leu Val Thr Glu Gln Val Ala Glu Ser Thr Ala Thr
Val Ser Trp Asp 805 810 815Pro Val Glu Ala Asp Ile Asp Arg Tyr Val
Val Arg Tyr Thr Ser Ala 820 825 830Asp Gly Glu Thr Arg Glu Ile Pro
Val Arg Lys Glu Lys Ser Ser Thr 835 840 845Val Leu Thr Gly Leu Arg
Pro Gly Val Glu Tyr Thr Val Gln Val Trp 850 855 860Ala Gln Lys Gly
Ala Arg Glu Ser Lys Lys Ala Lys Thr Lys Ala Pro865 870 875 880Thr
Glu Ile Asp Ser Pro Lys Asn Leu Val Thr Asn Arg Val Thr Glu 885 890
895Asn Thr Ala Thr Ile Ser Trp Asp Pro Val Arg Ala Asn Ile Asp Arg
900 905 910Tyr Met Val Arg Tyr Thr Ser Ala Asp Gly Glu Thr Lys Glu
Ile Pro 915 920 925Val Ser Lys Asp Gln Ser Asn Thr Ile Leu Thr Gly
Leu Lys Pro Gly 930 935 940Met Glu Tyr Thr Ile His Val Trp Ala Gln
Lys Gly Ala Arg Glu Ser945 950 955 960Lys Lys Ala Asp Thr Lys Ala
Leu Thr Glu Ile Asp Pro Pro Arg Asn 965 970 975Leu Arg Pro Phe Gly
Val Thr His Ser Gly Gly Val Leu Thr Trp Leu 980 985 990Pro Pro Ser
Ala Gln Ile Asp Gly Tyr Ile Leu Thr Tyr Gln Phe Pro 995 1000
1005Asn Gly Thr Val Lys Gly Val Glu Leu Pro Arg Gly Gln Gln Arg Phe
1010 1015 1020Glu Leu Gln Asp Leu Glu Gln Gly Val Thr Tyr Pro Val
Ser Leu Val1025 1030 1035 1040Ala Phe Lys Gly Asn Gln Arg Ser Arg
Thr Val Ser Thr Thr Leu Ser 1045 1050 1055Thr Val Asp Ala Arg Phe
Pro His Pro Ser Asp Cys Ser Gln Val Gln 1060 1065 1070Gln Asn Thr
Asn Ala Ala Ser Gly Leu Tyr Thr Ile Tyr Leu Asn Gly 1075 1080
1085Asp Ala Ser Arg Pro Met Gln Val Tyr Cys Asp Met Asp Thr Asp Gly
1090 1095 1100Gly Gly Trp Ile Val Phe Gln Arg Arg Asn Thr Gly Gln
Leu Asp Phe1105 1110 1115 1120Phe Lys Arg Trp Arg Ser Tyr Val Glu
Gly Phe Gly Asp Pro Met Lys 1125 1130 1135Glu Phe Trp Leu Gly Leu
Asp Lys Leu His Asn Leu Thr Thr Gly Thr 1140 1145 1150Thr Thr Arg
Tyr Glu Val Arg Ala Asp Leu Gln Thr Phe Asn Glu Ser 1155 1160
1165Ala Tyr Ala Val Tyr Asp Phe Phe Gln Val Ala Ser Ser Lys Glu Arg
1170 1175 1180Tyr Lys Leu Ser Val Gly Lys Tyr Arg Gly Thr Ala Gly
Asp Ala Leu1185 1190 1195 1200Thr Tyr His Asn Gly Trp Lys Phe Thr
Thr Phe Asp Arg Asp Ser Asp 1205 1210 1215Ile Ala Leu Ser Asn Cys
Ala Leu Thr His His Gly Gly Trp Trp Tyr 1220 1225 1230Lys Asn Cys
His Leu Ala Asn Pro Asn Gly Lys Tyr Gly Glu Thr Lys 1235 1240
1245His Ser Glu Gly Val Asn Trp Glu Pro Trp Lys Gly His Glu Phe Ser
1250 1255 1260Ile Pro Tyr Val Glu Leu Lys Ile Arg Pro Phe Gly Tyr
Ser Arg Asp1265 1270 1275 1280Arg Phe Ser Gly Arg Lys Lys Arg Ser
Ile Gly Lys Ala Arg Met Phe 1285 1290 129533885DNAHomo
sapiensCDS(1)...(3885)Human tenascin-W 3atg ttc cgc ttc cct atg ggg
ctc ctg ctt ggc tct gtg ctc ctg gtg 48Met Phe Arg Phe Pro Met Gly
Leu Leu Leu Gly Ser Val Leu Leu Val 1 5 10 15gct tcg gcc cca gcc
act ctg gag cct ccc ggc tgc agc aac aag gag 96Ala Ser Ala Pro Ala
Thr Leu Glu Pro Pro Gly Cys Ser Asn Lys Glu 20 25 30caa cag gtc act
gtc agc cac acc tac aag atc gat gtg ccc aag tct 144Gln Gln Val Thr
Val Ser His Thr Tyr Lys Ile Asp Val Pro Lys Ser 35 40 45gcc ttg gtt
cag gtt gac gct gac cct cag ccc ctc agt gac gat ggg 192Ala Leu Val
Gln Val Asp Ala Asp Pro Gln Pro Leu Ser Asp Asp Gly 50 55 60gct tcg
ctc ttg gcc ctg ggg gag gcc agg gag gaa cag aac atc atc 240Ala Ser
Leu Leu Ala Leu Gly Glu Ala Arg Glu Glu Gln Asn Ile Ile 65 70 75
80ttc agg cac aac atc cgc ctt cag acg cca cag aag gac tgc gag ttg
288Phe Arg His Asn Ile Arg Leu Gln Thr Pro Gln Lys Asp Cys Glu Leu
85 90 95gca ggc agt gtc cag gac ctc ctg gcc cgg gtg aag aag ctg gag
gaa 336Ala Gly Ser Val Gln Asp Leu Leu Ala Arg Val Lys Lys Leu Glu
Glu 100 105 110gag atg gtg gag atg aag gaa cag tgt agt gcc cag cgc
tgc tgc cag 384Glu Met Val Glu Met Lys Glu Gln Cys Ser Ala Gln Arg
Cys Cys Gln 115 120 125gga gtc act gat cta agc cgc cac tgc agc ggc
cac ggg acc ttc tcc 432Gly Val Thr Asp Leu Ser Arg His Cys Ser Gly
His Gly Thr Phe Ser 130 135 140ctg gag acc tgc agc tgc cac tgc gaa
gag ggc agg gag ggc ccc gcc 480Leu Glu Thr Cys Ser Cys His Cys Glu
Glu Gly Arg Glu Gly Pro Ala145 150 155 160tgc gag cgg ctg gcc tgc
ccc ggg gcg tgc agc ggc cac ggg cgt tgc 528Cys Glu Arg Leu Ala Cys
Pro Gly Ala Cys Ser Gly His Gly Arg Cys 165 170 175gtg gac ggg cgc
tgc ctg tgc cat gag ccc tac gtg ggt gcc gac tgc 576Val Asp Gly Arg
Cys Leu Cys His Glu Pro Tyr Val Gly Ala Asp Cys 180 185 190ggc tac
ccg gcc tgc cct gag aac tgc agc gga cac ggc gag tgc gtg 624Gly Tyr
Pro Ala Cys Pro Glu Asn Cys Ser Gly His Gly Glu Cys Val 195 200
205cgc ggc gtg tgc cag tgc cac gaa gac ttc atg tcg gag gac tgc agc
672Arg Gly Val Cys Gln Cys His Glu Asp Phe Met Ser Glu Asp Cys Ser
210 215 220gag aag cgc tgt ccc ggc gac tgc agc ggc cac ggc ttc tgt
gac acg 720Glu Lys Arg Cys Pro Gly Asp Cys Ser Gly His Gly Phe Cys
Asp Thr225 230 235 240ggc gag tgc tac tgc gag gag ggc ttc aca ggc
ctg gac tgt gcc cag 768Gly Glu Cys Tyr Cys Glu Glu Gly Phe Thr Gly
Leu Asp Cys Ala Gln 245 250 255gtg gtc acc cca cag ggc ctg cag ctg
ctc aag aac acg gag gat tct 816Val Val Thr Pro Gln Gly Leu Gln Leu
Leu Lys Asn Thr Glu Asp Ser 260 265 270ctg ctg gtg agc tgg gag ccc
tcc agc cag gtg gat cac tac ctc ctc 864Leu Leu Val Ser Trp Glu Pro
Ser Ser Gln Val Asp His Tyr Leu Leu 275 280 285agc tac tac ccc ctg
ggg aag gag ctc tct ggg aag cag atc caa gtg 912Ser Tyr Tyr Pro Leu
Gly Lys Glu Leu Ser Gly Lys Gln Ile Gln Val 290 295 300ccc aag gag
cag cac agc tat gag att ctt ggt ttg ctg cct gga acc 960Pro Lys Glu
Gln His Ser Tyr Glu Ile Leu Gly Leu Leu Pro Gly Thr305 310 315
320aag tac ata gtc acc ctg cgt aac gtc aag aat gaa gtt tct agc agc
1008Lys Tyr Ile Val Thr Leu Arg Asn Val Lys Asn Glu Val Ser Ser Ser
325 330 335cca cag cat cta ctt gcc acc aca gac ctt gct gtg ctt ggc
act gcc 1056Pro Gln His Leu Leu Ala Thr Thr Asp Leu Ala Val Leu Gly
Thr Ala 340 345 350tgg gtg aca gat gag act gag aac tcc ctt gac gtg
gag tgg gaa aac 1104Trp Val Thr Asp Glu Thr Glu Asn Ser Leu Asp Val
Glu Trp Glu Asn 355 360 365ccc tca act gag gtg gac tac tac aag ctg
cga tat ggc ccc atg aca 1152Pro Ser Thr Glu Val Asp Tyr Tyr Lys Leu
Arg Tyr Gly Pro Met Thr 370 375 380gga cag gag gta gct gag gtc act
gtg ccc aag agc agt gac ccc aag 1200Gly Gln Glu Val Ala Glu Val Thr
Val Pro Lys Ser Ser Asp Pro Lys385 390 395 400agc cga tat gac atc
act ggt ctg cac ccg ggg act gag tat aag atc 1248Ser Arg Tyr Asp Ile
Thr Gly Leu His Pro Gly Thr Glu Tyr Lys Ile 405 410 415acg gtg gtg
ccc atg aga gga gag ctg gag ggc aag ccg atc ctc ctg 1296Thr Val Val
Pro Met Arg Gly Glu Leu Glu Gly Lys Pro Ile Leu Leu 420 425 430aat
ggc agg aca gaa att gac agt cca acc aat gtt gtc act gat cga 1344Asn
Gly Arg Thr Glu Ile Asp Ser Pro Thr Asn Val Val Thr Asp Arg 435 440
445gtg act gaa gac aca gca act gtc tcc tgg gac cca gtg cag gct gtc
1392Val Thr Glu Asp Thr Ala Thr Val Ser Trp Asp Pro Val Gln Ala Val
450 455 460ata gac aag tat gta gtg cgc tac act tct gct gat ggg gac
acc aag 1440Ile Asp Lys Tyr Val Val Arg Tyr Thr Ser Ala Asp Gly Asp
Thr Lys465 470 475 480gaa atg gca gtg cac aag gat gag agc agc act
gtc ctg acg ggc ctg 1488Glu Met Ala Val His Lys Asp Glu Ser Ser Thr
Val Leu Thr Gly Leu 485 490 495aag cca gga gag gca tac aag gtc tac
gtg tgg gct gaa agg ggc aac 1536Lys Pro Gly Glu Ala Tyr Lys Val Tyr
Val Trp Ala Glu Arg Gly Asn 500 505 510cag ggg agc aag aaa gct gac
acc aat gcc ctc aca gaa att gac agc 1584Gln Gly Ser Lys Lys Ala Asp
Thr Asn Ala Leu Thr Glu Ile Asp Ser 515 520 525cca gca aac ctg gtg
act gac cgg gtg act gag aat acc gcc acc atc 1632Pro Ala Asn Leu Val
Thr Asp Arg Val Thr Glu Asn Thr Ala Thr Ile 530 535 540tcc tgg gac
ccg gta cag gcc acc att gac aag tac gtg gtg cgc tac 1680Ser Trp Asp
Pro Val Gln Ala Thr Ile Asp Lys Tyr Val Val Arg Tyr545 550 555
560acc tct gct gac gac caa gag acc aga gag gtt ctg gtg ggg aag gag
1728Thr Ser Ala Asp Asp Gln Glu Thr Arg Glu Val Leu Val Gly Lys Glu
565 570 575cag agc agc act gtc ctg aca ggc ctg agg cca ggt gtg gag
tac aca 1776Gln Ser Ser Thr Val Leu Thr Gly Leu Arg Pro Gly Val Glu
Tyr Thr 580 585 590gtg cat gtc tgg gcc cag aag ggg gac cga gag agc
aag aag gct gac 1824Val His Val Trp Ala Gln Lys Gly Asp Arg Glu Ser
Lys Lys Ala Asp 595 600 605acc aac gcc ccg aca gat att gac agc ccc
aaa aac ctg gtg act gac 1872Thr Asn Ala Pro Thr Asp Ile Asp Ser Pro
Lys Asn Leu Val Thr Asp 610 615 620cgg gtg aca gag aat atg gcc acg
gtc tcc tgg gac ccg gtg cag gcc 1920Arg Val Thr Glu Asn Met Ala Thr
Val Ser Trp Asp Pro Val Gln Ala625 630 635 640gcc att gac aag tac
gtg gtg cgc tac acc tct gct ggt gga gag acc 1968Ala Ile Asp Lys Tyr
Val Val Arg Tyr Thr Ser Ala Gly Gly Glu Thr 645 650 655agg gag gtt
ccg gtg ggg aag gag cag agc agc aca gtc ctg aca ggc 2016Arg Glu Val
Pro Val Gly Lys Glu Gln Ser Ser Thr Val Leu Thr Gly 660 665 670ctg
aga ccg ggt atg gag tac atg gtg cac gtg tgg gcc cag aag ggg 2064Leu
Arg Pro Gly Met Glu Tyr Met Val His Val Trp Ala Gln Lys Gly 675 680
685gac cag gag agc aag aag gcc gac acc aag gcc cag aca gac att gac
2112Asp Gln Glu Ser Lys Lys Ala Asp Thr Lys Ala Gln Thr Asp Ile Asp
690 695 700agc ccc caa aac ctg gtg acc gac cgg gtg aca gag aat atg
gcc act 2160Ser Pro Gln Asn Leu Val Thr Asp Arg Val Thr Glu Asn Met
Ala Thr705 710 715 720gtc tcc tgg gac ccg gtg cgg gcc acc att gac
agg tat gtg gtg cgc 2208Val Ser Trp Asp Pro Val Arg Ala Thr Ile Asp
Arg Tyr Val Val Arg 725 730 735tac acc tct gcc aag gac gga gag acc
agg gag gtt ccg gtg ggg aag 2256Tyr Thr Ser Ala Lys Asp Gly Glu Thr
Arg Glu Val Pro Val Gly Lys 740 745 750gag cag agt agc act gtc ctg
acg ggc ctg agg ccg ggt gtg gag tac 2304Glu Gln Ser Ser Thr Val Leu
Thr Gly Leu Arg Pro Gly Val Glu Tyr 755 760 765acg gtg cac gtg tgg
gcc cag aag ggg gcc cag gag agc aag aag gct 2352Thr Val His Val Trp
Ala Gln Lys Gly Ala Gln Glu Ser Lys Lys Ala 770 775 780gac acc aag
gcc cag aca gac att gac agc ccc caa aac ctg gtc act 2400Asp Thr Lys
Ala Gln Thr Asp Ile Asp Ser Pro Gln Asn Leu Val Thr785 790 795
800gac tgg gtg aca gag aat aca gcc act gtc tcc tgg gac ccg gtg cag
2448Asp Trp Val Thr Glu Asn Thr Ala Thr Val Ser Trp Asp Pro Val Gln
805 810 815gcc acc att gac agg tat gtg gtg cac tac acg tct gcc aac
gga gag 2496Ala Thr Ile Asp Arg Tyr Val Val His Tyr Thr Ser Ala Asn
Gly Glu 820 825 830acc agg gag gtt cca gtg ggg aag gag cag agc agc
act gtc ctg acg 2544Thr Arg Glu Val Pro Val Gly Lys Glu Gln Ser Ser
Thr Val Leu Thr 835 840 845ggc ctg agg ccg ggc atg gag tac acg gtg
cac gtg tgg gcc cag aag 2592Gly Leu Arg Pro Gly Met Glu Tyr Thr Val
His Val Trp Ala Gln Lys 850 855 860ggg aac cag gag agc aag aag gct
gac acc aag gcc cag aca gaa att 2640Gly Asn Gln Glu Ser Lys Lys Ala
Asp Thr Lys Ala Gln Thr Glu Ile865 870 875 880gac ggc ccc aaa aac
cta gtg act gac tgg gtg acg gag aat atg gcc 2688Asp Gly Pro Lys Asn
Leu Val Thr Asp Trp Val Thr Glu Asn Met Ala 885 890 895act gtc tcc
tgg gac ccg gtt cag gcc acc att gac aag tac atg gtg 2736Thr Val Ser
Trp Asp Pro Val Gln Ala Thr Ile Asp Lys Tyr Met Val 900 905 910cgc
tac acc tct gct gac gga gag acc agg gag gtt ccg gtg ggg aag 2784Arg
Tyr Thr Ser Ala Asp Gly Glu Thr Arg Glu Val Pro Val Gly Lys 915 920
925gag cac agc agc act gtc ctg acg ggc ctg aga cca ggc atg gag tac
2832Glu His Ser Ser Thr Val Leu Thr Gly Leu Arg Pro Gly Met Glu Tyr
930 935 940atg gtg cac gtg tgg gcc cag aag ggg gcc cag gag agc aag
aag gct 2880Met Val His Val Trp Ala Gln Lys Gly Ala Gln Glu Ser Lys
Lys Ala945 950 955 960gac acc aag gcc
cag aca gaa ctc gac cct ccc aga aac ctt cgt cca 2928Asp Thr Lys Ala
Gln Thr Glu Leu Asp Pro Pro Arg Asn Leu Arg Pro 965 970 975tct gct
gta acg cag tct ggt ggc ata ttg acc tgg acg ccc ccc tct 2976Ser Ala
Val Thr Gln Ser Gly Gly Ile Leu Thr Trp Thr Pro Pro Ser 980 985
990gct cag atc cac ggc tac att ctg act tac cag ttc cca gat ggc aca
3024Ala Gln Ile His Gly Tyr Ile Leu Thr Tyr Gln Phe Pro Asp Gly Thr
995 1000 1005gtt aag gag atg cag ctg gga cgg gaa gac cag agg ttt
gcg ttg caa 3072Val Lys Glu Met Gln Leu Gly Arg Glu Asp Gln Arg Phe
Ala Leu Gln 1010 1015 1020ggc ctt gag caa ggc gcc acc tac cct gtc
tcc ctt gtt gcc ttt aag 3120Gly Leu Glu Gln Gly Ala Thr Tyr Pro Val
Ser Leu Val Ala Phe Lys1025 1030 1035 1040ggt ggt cgc cgg agc aga
aat gta tcc acc acc ctc tcc aca gtt ggt 3168Gly Gly Arg Arg Ser Arg
Asn Val Ser Thr Thr Leu Ser Thr Val Gly 1045 1050 1055gcc cgt ttc
cca cac cct tcg gac tgc agt cag gtt cag cag aac agc 3216Ala Arg Phe
Pro His Pro Ser Asp Cys Ser Gln Val Gln Gln Asn Ser 1060 1065
1070aat gcc gcc agt ggt ctg tac acc atc tac ctg cat ggc gat gcc agc
3264Asn Ala Ala Ser Gly Leu Tyr Thr Ile Tyr Leu His Gly Asp Ala Ser
1075 1080 1085cgg ccc ctg cag gtg tac tgt gac atg gaa acg gac gga
ggt ggc tgg 3312Arg Pro Leu Gln Val Tyr Cys Asp Met Glu Thr Asp Gly
Gly Gly Trp 1090 1095 1100att gtc ttc cag agg cgg aac act ggg cag
ctg gat ttc ttc aag cga 3360Ile Val Phe Gln Arg Arg Asn Thr Gly Gln
Leu Asp Phe Phe Lys Arg1105 1110 1115 1120tgg agg agc tat gtg gaa
ggc ttt ggg gac ccc atg aag gag ttc tgg 3408Trp Arg Ser Tyr Val Glu
Gly Phe Gly Asp Pro Met Lys Glu Phe Trp 1125 1130 1135ctt gga ctt
gac aag cta cac aac ctc acc acc ggc act cca gcg cgg 3456Leu Gly Leu
Asp Lys Leu His Asn Leu Thr Thr Gly Thr Pro Ala Arg 1140 1145
1150tat gag gtg aga gtg gat tta cag act gcc aat gaa tct gcc tat gct
3504Tyr Glu Val Arg Val Asp Leu Gln Thr Ala Asn Glu Ser Ala Tyr Ala
1155 1160 1165ata tat gat ttc ttc caa gtg gcc tcc agc aag gag cgg
tat aag ctg 3552Ile Tyr Asp Phe Phe Gln Val Ala Ser Ser Lys Glu Arg
Tyr Lys Leu 1170 1175 1180aca gtt ggg aaa tac aga ggc acg gca ggg
gat gct ctt act tac cac 3600Thr Val Gly Lys Tyr Arg Gly Thr Ala Gly
Asp Ala Leu Thr Tyr His1185 1190 1195 1200aat gga tgg aag ttt aca
act ttt gac aga gac aat gat atc gca ctc 3648Asn Gly Trp Lys Phe Thr
Thr Phe Asp Arg Asp Asn Asp Ile Ala Leu 1205 1210 1215agc aac tgt
gcc ctg aca cat cat ggt ggc tgg tgg tat aag aac tgc 3696Ser Asn Cys
Ala Leu Thr His His Gly Gly Trp Trp Tyr Lys Asn Cys 1220 1225
1230cac ttg gcc aac cct aat ggc aga tat ggg gag acc aag cac agt gag
3744His Leu Ala Asn Pro Asn Gly Arg Tyr Gly Glu Thr Lys His Ser Glu
1235 1240 1245ggg gtg aac tgg gag cct tgg aaa gga cat gaa ttc tcc
att cct tac 3792Gly Val Asn Trp Glu Pro Trp Lys Gly His Glu Phe Ser
Ile Pro Tyr 1250 1255 1260gtg gag ttg aaa atc cgc cct cat ggc tac
agc agg gag cct gtc ctg 3840Val Glu Leu Lys Ile Arg Pro His Gly Tyr
Ser Arg Glu Pro Val Leu1265 1270 1275 1280ggc aga aag aag cgg acg
ctg aga gga agg ctg cga acg ttc tga 3885Gly Arg Lys Lys Arg Thr Leu
Arg Gly Arg Leu Arg Thr Phe * 1285 129041294PRTHomo sapiens 4Met
Phe Arg Phe Pro Met Gly Leu Leu Leu Gly Ser Val Leu Leu Val 1 5 10
15Ala Ser Ala Pro Ala Thr Leu Glu Pro Pro Gly Cys Ser Asn Lys Glu
20 25 30Gln Gln Val Thr Val Ser His Thr Tyr Lys Ile Asp Val Pro Lys
Ser 35 40 45Ala Leu Val Gln Val Asp Ala Asp Pro Gln Pro Leu Ser Asp
Asp Gly 50 55 60Ala Ser Leu Leu Ala Leu Gly Glu Ala Arg Glu Glu Gln
Asn Ile Ile65 70 75 80Phe Arg His Asn Ile Arg Leu Gln Thr Pro Gln
Lys Asp Cys Glu Leu 85 90 95Ala Gly Ser Val Gln Asp Leu Leu Ala Arg
Val Lys Lys Leu Glu Glu 100 105 110Glu Met Val Glu Met Lys Glu Gln
Cys Ser Ala Gln Arg Cys Cys Gln 115 120 125Gly Val Thr Asp Leu Ser
Arg His Cys Ser Gly His Gly Thr Phe Ser 130 135 140Leu Glu Thr Cys
Ser Cys His Cys Glu Glu Gly Arg Glu Gly Pro Ala145 150 155 160Cys
Glu Arg Leu Ala Cys Pro Gly Ala Cys Ser Gly His Gly Arg Cys 165 170
175Val Asp Gly Arg Cys Leu Cys His Glu Pro Tyr Val Gly Ala Asp Cys
180 185 190Gly Tyr Pro Ala Cys Pro Glu Asn Cys Ser Gly His Gly Glu
Cys Val 195 200 205Arg Gly Val Cys Gln Cys His Glu Asp Phe Met Ser
Glu Asp Cys Ser 210 215 220Glu Lys Arg Cys Pro Gly Asp Cys Ser Gly
His Gly Phe Cys Asp Thr225 230 235 240Gly Glu Cys Tyr Cys Glu Glu
Gly Phe Thr Gly Leu Asp Cys Ala Gln 245 250 255Val Val Thr Pro Gln
Gly Leu Gln Leu Leu Lys Asn Thr Glu Asp Ser 260 265 270Leu Leu Val
Ser Trp Glu Pro Ser Ser Gln Val Asp His Tyr Leu Leu 275 280 285Ser
Tyr Tyr Pro Leu Gly Lys Glu Leu Ser Gly Lys Gln Ile Gln Val 290 295
300Pro Lys Glu Gln His Ser Tyr Glu Ile Leu Gly Leu Leu Pro Gly
Thr305 310 315 320Lys Tyr Ile Val Thr Leu Arg Asn Val Lys Asn Glu
Val Ser Ser Ser 325 330 335Pro Gln His Leu Leu Ala Thr Thr Asp Leu
Ala Val Leu Gly Thr Ala 340 345 350Trp Val Thr Asp Glu Thr Glu Asn
Ser Leu Asp Val Glu Trp Glu Asn 355 360 365Pro Ser Thr Glu Val Asp
Tyr Tyr Lys Leu Arg Tyr Gly Pro Met Thr 370 375 380Gly Gln Glu Val
Ala Glu Val Thr Val Pro Lys Ser Ser Asp Pro Lys385 390 395 400Ser
Arg Tyr Asp Ile Thr Gly Leu His Pro Gly Thr Glu Tyr Lys Ile 405 410
415Thr Val Val Pro Met Arg Gly Glu Leu Glu Gly Lys Pro Ile Leu Leu
420 425 430Asn Gly Arg Thr Glu Ile Asp Ser Pro Thr Asn Val Val Thr
Asp Arg 435 440 445Val Thr Glu Asp Thr Ala Thr Val Ser Trp Asp Pro
Val Gln Ala Val 450 455 460Ile Asp Lys Tyr Val Val Arg Tyr Thr Ser
Ala Asp Gly Asp Thr Lys465 470 475 480Glu Met Ala Val His Lys Asp
Glu Ser Ser Thr Val Leu Thr Gly Leu 485 490 495Lys Pro Gly Glu Ala
Tyr Lys Val Tyr Val Trp Ala Glu Arg Gly Asn 500 505 510Gln Gly Ser
Lys Lys Ala Asp Thr Asn Ala Leu Thr Glu Ile Asp Ser 515 520 525Pro
Ala Asn Leu Val Thr Asp Arg Val Thr Glu Asn Thr Ala Thr Ile 530 535
540Ser Trp Asp Pro Val Gln Ala Thr Ile Asp Lys Tyr Val Val Arg
Tyr545 550 555 560Thr Ser Ala Asp Asp Gln Glu Thr Arg Glu Val Leu
Val Gly Lys Glu 565 570 575Gln Ser Ser Thr Val Leu Thr Gly Leu Arg
Pro Gly Val Glu Tyr Thr 580 585 590Val His Val Trp Ala Gln Lys Gly
Asp Arg Glu Ser Lys Lys Ala Asp 595 600 605Thr Asn Ala Pro Thr Asp
Ile Asp Ser Pro Lys Asn Leu Val Thr Asp 610 615 620Arg Val Thr Glu
Asn Met Ala Thr Val Ser Trp Asp Pro Val Gln Ala625 630 635 640Ala
Ile Asp Lys Tyr Val Val Arg Tyr Thr Ser Ala Gly Gly Glu Thr 645 650
655Arg Glu Val Pro Val Gly Lys Glu Gln Ser Ser Thr Val Leu Thr Gly
660 665 670Leu Arg Pro Gly Met Glu Tyr Met Val His Val Trp Ala Gln
Lys Gly 675 680 685Asp Gln Glu Ser Lys Lys Ala Asp Thr Lys Ala Gln
Thr Asp Ile Asp 690 695 700Ser Pro Gln Asn Leu Val Thr Asp Arg Val
Thr Glu Asn Met Ala Thr705 710 715 720Val Ser Trp Asp Pro Val Arg
Ala Thr Ile Asp Arg Tyr Val Val Arg 725 730 735Tyr Thr Ser Ala Lys
Asp Gly Glu Thr Arg Glu Val Pro Val Gly Lys 740 745 750Glu Gln Ser
Ser Thr Val Leu Thr Gly Leu Arg Pro Gly Val Glu Tyr 755 760 765Thr
Val His Val Trp Ala Gln Lys Gly Ala Gln Glu Ser Lys Lys Ala 770 775
780Asp Thr Lys Ala Gln Thr Asp Ile Asp Ser Pro Gln Asn Leu Val
Thr785 790 795 800Asp Trp Val Thr Glu Asn Thr Ala Thr Val Ser Trp
Asp Pro Val Gln 805 810 815Ala Thr Ile Asp Arg Tyr Val Val His Tyr
Thr Ser Ala Asn Gly Glu 820 825 830Thr Arg Glu Val Pro Val Gly Lys
Glu Gln Ser Ser Thr Val Leu Thr 835 840 845Gly Leu Arg Pro Gly Met
Glu Tyr Thr Val His Val Trp Ala Gln Lys 850 855 860Gly Asn Gln Glu
Ser Lys Lys Ala Asp Thr Lys Ala Gln Thr Glu Ile865 870 875 880Asp
Gly Pro Lys Asn Leu Val Thr Asp Trp Val Thr Glu Asn Met Ala 885 890
895Thr Val Ser Trp Asp Pro Val Gln Ala Thr Ile Asp Lys Tyr Met Val
900 905 910Arg Tyr Thr Ser Ala Asp Gly Glu Thr Arg Glu Val Pro Val
Gly Lys 915 920 925Glu His Ser Ser Thr Val Leu Thr Gly Leu Arg Pro
Gly Met Glu Tyr 930 935 940Met Val His Val Trp Ala Gln Lys Gly Ala
Gln Glu Ser Lys Lys Ala945 950 955 960Asp Thr Lys Ala Gln Thr Glu
Leu Asp Pro Pro Arg Asn Leu Arg Pro 965 970 975Ser Ala Val Thr Gln
Ser Gly Gly Ile Leu Thr Trp Thr Pro Pro Ser 980 985 990Ala Gln Ile
His Gly Tyr Ile Leu Thr Tyr Gln Phe Pro Asp Gly Thr 995 1000
1005Val Lys Glu Met Gln Leu Gly Arg Glu Asp Gln Arg Phe Ala Leu Gln
1010 1015 1020Gly Leu Glu Gln Gly Ala Thr Tyr Pro Val Ser Leu Val
Ala Phe Lys1025 1030 1035 1040Gly Gly Arg Arg Ser Arg Asn Val Ser
Thr Thr Leu Ser Thr Val Gly 1045 1050 1055Ala Arg Phe Pro His Pro
Ser Asp Cys Ser Gln Val Gln Gln Asn Ser 1060 1065 1070Asn Ala Ala
Ser Gly Leu Tyr Thr Ile Tyr Leu His Gly Asp Ala Ser 1075 1080
1085Arg Pro Leu Gln Val Tyr Cys Asp Met Glu Thr Asp Gly Gly Gly Trp
1090 1095 1100Ile Val Phe Gln Arg Arg Asn Thr Gly Gln Leu Asp Phe
Phe Lys Arg1105 1110 1115 1120Trp Arg Ser Tyr Val Glu Gly Phe Gly
Asp Pro Met Lys Glu Phe Trp 1125 1130 1135Leu Gly Leu Asp Lys Leu
His Asn Leu Thr Thr Gly Thr Pro Ala Arg 1140 1145 1150Tyr Glu Val
Arg Val Asp Leu Gln Thr Ala Asn Glu Ser Ala Tyr Ala 1155 1160
1165Ile Tyr Asp Phe Phe Gln Val Ala Ser Ser Lys Glu Arg Tyr Lys Leu
1170 1175 1180Thr Val Gly Lys Tyr Arg Gly Thr Ala Gly Asp Ala Leu
Thr Tyr His1185 1190 1195 1200Asn Gly Trp Lys Phe Thr Thr Phe Asp
Arg Asp Asn Asp Ile Ala Leu 1205 1210 1215Ser Asn Cys Ala Leu Thr
His His Gly Gly Trp Trp Tyr Lys Asn Cys 1220 1225 1230His Leu Ala
Asn Pro Asn Gly Arg Tyr Gly Glu Thr Lys His Ser Glu 1235 1240
1245Gly Val Asn Trp Glu Pro Trp Lys Gly His Glu Phe Ser Ile Pro Tyr
1250 1255 1260Val Glu Leu Lys Ile Arg Pro His Gly Tyr Ser Arg Glu
Pro Val Leu1265 1270 1275 1280Gly Arg Lys Lys Arg Thr Leu Arg Gly
Arg Leu Arg Thr Phe 1285 1290525DNAMus
musculusprimer_bind(1)...(25)First polymerase chain reaction primer
5tagcagccca cagcatctac ttgcc 25627DNAMus
musculusprimer_bind(1)...(27)First polymerase chain reaction primer
6attgctgttc tgctgaacct gactgca 27734DNAMus
musculusprimer_bind(1)...(34)Second polymerase chain reaction
primer 7atggatccag aaattgacgg ccccaaaaac ctag 34833DNAMus
musculusprimer_bind(1)...(33)Second polymerase chain reaction
primer 8ataagcttgt ggagagggtg gtggatacat ttc 33924DNAMus
musculusprimer_bind(1)...(24)First PCR primer for sequencing 5' end
9aggagatggt ggctgtattt tcgg 241024DNAMus
musculusprimer_bind(1)...(24)First PCR primer for sequencing 5' end
10agcctcttgc tgagtggaga tgcc 241130DNAMus
musculusprimer_bind(1)...(30)Second PCR primer for sequencing 5'
end 11tagaattcgg tcacctgatt ggtcactagg 301222DNAMus
musculusprimer_bind(1)...(22)Second PCR primer for sequencing 5'
end 12ttatgatgtg ccagattatg cc 221326DNAMus
musculusprimer_bind(1)...(26)First PCR reaction for sequencing 3'
end 13ctcaaattga tggctacatt ttgacc 261424DNAMus
musculusprimer_bind(1)...(24)First PCR primer for sequencing 3' end
14aagccgacaa ccttgattgg agac 241522DNAMus
musculusprimer_bind(1)...(22)Second PCR primer for sequencing 3'
end 15taccagttcc caaatggcac cg 221621DNAMus
musculusprimer_bind(1)...(21)Second PCR primer for sequencing 3'
end 16aaacctctgg cgaagaagtc c 211720DNAHomo
sapiensprimer_bind(1)...(20)hTNW1 17catcctggag ggtctgctcc
201820DNAHomo sapiensprimer_bind(1)...(20)hTNW2 18gggcattggt
gtcagctttc 201928DNAHomo sapiensprimer_bind(1)...(28)hTNW3
19gactcgagct ttccaaggat gagtctcc 282026DNAHomo
sapiensprimer_bind(1)...(26)hTNW4 20gaggatcccc tggttgcccc tttcag
262120DNAHomo sapiensprimer_bind(1)...(20)hTNW5 21gcgctacact
tctgctgatg 202218DNAHomo sapiensprimer_bind(1)...(18)hTNW6
22ctgtggagag ggtggtgg 182327DNAHomo
sapiensprimer_bind(1)...(27)hTNW7 23gactcgagtg cacaaggatg agagcag
272428DNAHomo sapiensprimer_bind(1)...(28)hTNW8 24gaggatccac
ccttaaaggc aacaaggg 282520DNAHomo sapiensprimer_bind(1)...(20)hTNW9
25cgcagtctgg tggcatattg 202619DNAHomo
sapiensprimer_bind(1)...(19)hTNW10 26catgatttgt tctgcgggc
192728DNAHomo sapiensprimer_bind(1)...(28)hTNW11 27gactcgagcg
gctacattct gacttacc 282829DNAHomo
sapiensprimer_bind(1)...(29)hTNW12 28gaggatcctc agtgatggtg
atggtgatg 29
* * * * *